

---

*Research Article: New Research | Sensory and Motor Systems*

## **Insulin-dependent maturation of newly generated olfactory sensory neurons after injury**

<https://doi.org/10.1523/ENEURO.0168-21.2021>

**Cite as:** eNeuro 2021; 10.1523/ENEURO.0168-21.2021

Received: 16 April 2021

Accepted: 20 April 2021

---

*This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data.*

**Alerts:** Sign up at [www.eneuro.org/alerts](http://www.eneuro.org/alerts) to receive customized email alerts when the fully formatted version of this article is published.

Copyright © 2021 Kuboki et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

1 **Insulin-dependent maturation of newly generated olfactory**  
2 **sensory neurons after injury**

3  
4 Abbreviated title: Role of insulin in olfactory neuron maturation

5  
6 Akihito Kuboki<sup>1,2</sup>, Shu Kikuta<sup>3</sup>, Nobuyoshi Otori<sup>1</sup>, Hiromi Kojima<sup>1</sup>, Ichiro Matsumoto<sup>2</sup>,  
7 Johannes Reisert<sup>2</sup>, and Tatsuya Yamasoba<sup>3</sup>

8  
9 <sup>1</sup>Department of Otolaryngology, Jikei University School of Medicine, 3-25-8 Nishi-shinbashi,  
10 Minato-ku, Tokyo 105-8461, Japan

11 <sup>2</sup>Monell Chemical Senses Center, Philadelphia, Pennsylvania 19104, USA

12 <sup>3</sup>Department of Otolaryngology, Graduate School of Medicine, University of Tokyo, 7-3-1  
13 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan

14  
15 To whom correspondence should be addressed: Shu Kikuta

16 Department of Otolaryngology, Graduate School of Medicine, The University of Tokyo, 7-3-1  
17 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

18 Tel/Fax: +81-3-5800-8665; E-mail: sh-kiku@m.u-tokyo.ac.jp

19  
20 **Pages: 48**

21 **Figs: 10; Table: 1**

22 **Word counts: Abstract, 250; Introduction, 580; Discussion, 1472**

23  
24 **Conflict of interest:** A.K. and S.K. are inventors in the patents of US (us 9931380, Medicament  
25 for treating olfactory disorder) and Japan (jp 6035524, Dysosmia therapeutic agent) that cover

26 the intellectual property presented in this paper. All other authors declare no competing

27 financial interests.

28

29 **Acknowledgments**

30 This study was supported by a grant-in-aid for scientific research (C) of the Japan Society for  
31 Promotion of Science grant 17K11354 (Shu Kikuta), Takeda Science Foundation grant (Shu  
32 Kikuta) and a National Institutes of Health grant R01DC016647 (Johannes Reisert).  
33 Immunohistochemistry and confocal microscopy were, in part, performed at the Monell  
34 Histology and Cellular Localization Core which is supported, in part, by funding from the  
35 NIH-NIDCD Core Grant 1P30DC011735-01 and also from grant G20OD020296 (infrastructure  
36 improvement at the Monell Chemical Senses Center). We thank Ms. Emi Usukura at the  
37 University of Tokyo for technical assistance. We also thank Prof. Kensaku Mori (University of  
38 Tokyo) for critical comments on this manuscript. Dr. Kazushige Touhara (University of Tokyo)  
39 provided the mOR-EG-GFP mice, and Drs Peter Mombaerts (Max Planck Research Unit for  
40 Neurogenetics) and Tom Bozza (Northwestern University) provided the I7-IRES-tauGFP mice.  
41 We thank Dr. Michael Tordoff (Monell Chemical Senses Center) for reading and providing  
42 helpful comments on this manuscript.

43 **Abstract**

44 Loss of olfactory sensory neurons (OSNs) after injury to the olfactory epithelium (OE) triggers  
45 the generation of OSNs that are incorporated into olfactory circuits to restore olfactory sensory  
46 perception. This study addresses how insulin receptor-mediated signaling affects the functional  
47 recovery of OSNs after OE injury. Insulin levels were reduced in mice by ablating the  
48 pancreatic beta cells via streptozotocin injections. These streptozotocin-induced diabetic and  
49 control mice were then intraperitoneally injected with the olfactotoxic drug methimazole to  
50 selectively ablate OSNs. The OE of diabetic and control mice regenerated similarly until day 14  
51 after injury. Thereafter, the OE of diabetic mice contained fewer mature and more apoptotic  
52 OSNs than control mice. Functionally, diabetic mice showed reduced electro-olfactogram  
53 responses and their olfactory bulbs had fewer c-Fos-active cells following odor stimulation, as  
54 well as performed worse in an odor-guided task compared to control mice. Insulin administered  
55 intranasally during day 8 to 13 after injury was sufficient to rescue recovery of OSNs in diabetic  
56 mice compared to control levels, while insulin administration between days 1 – 6 did not.  
57 During this critical time window on day 8 – 13 after injury, insulin receptors are highly  
58 expressed and intranasal application of an insulin receptor antagonist inhibits regeneration.  
59 Furthermore, an insulin-enriched environment could facilitate regeneration even in non-diabetic  
60 mice. These results indicate that insulin facilitates the regeneration of OSNs after injury and  
61 suggest a critical stage during recovery (8 – 13 days after injury) during which the maturation of  
62 newly generated OSNs is highly dependent on and promoted by insulin.

63

64 **Significance Statement**

65 Although insulin receptor signaling is known to have an influence on cellular processes such as  
66 proliferation and apoptosis, it is poorly understood whether the insulin influences the  
67 regeneration of olfactory sensory neurons (OSNs) after injury. We compared the maturation  
68 processes of new OSNs after the methimazole-induced loss of pre-existing OSNs between

69 diabetic and control mice. The results show that the regeneration of new OSNs depends on  
70 sufficient insulin levels during a specific temporal window, when insulin receptor expression is  
71 highly upregulated. Furthermore, an insulin-enriched environment via nasal insulin application  
72 during the critical period facilitates OSNs regeneration even in non-diabetic mice. The present  
73 results have implications for intranasal application of insulin as potential clinical therapeutics to  
74 facilitate OSNs regeneration after the injury.

75 **Introduction**

76 Tissue homeostasis in the nervous system is a fundamental mechanism for maintaining normal  
77 function and signal transmission within complicated neural networks, such as the olfactory  
78 system. The olfactory epithelium (OE) inside the nasal cavity harbors the olfactory sensory  
79 neurons (OSNs), which are directly responsible for detecting odors. A special property of OSNs  
80 is their ability to regenerate from progenitor cells throughout life (Schwob, 2002). In the OE,  
81 the ongoing incorporation of new OSNs is required to maintain the integrity of olfactory  
82 neuronal circuits for continuous monitoring of the external odor world (Mori and Sakano, 2011).

83         Insulin is a peptide hormone produced from pancreatic beta cells and is mainly  
84 involved in regulating glucose metabolism in the periphery. Insulin and insulin receptors are  
85 also present in the central nervous system, where they regulate neuronal growth, survival,  
86 proliferation, and differentiation (Wan et al., 1997; Aberg et al., 2000; Skeberdis et al., 2001;  
87 Chiu and Cline, 2010; Fernandez and Torres-Aleman, 2012). Thus, insulin signaling in the  
88 central nervous system is of significant interest because of the global increase in the incidence  
89 of diabetes mellitus as well as the associated metabolic and neuronal comorbidities (Blazquez et  
90 al., 2014).

91         Insulin receptors and the corresponding mRNA are expressed in the OE (Fernandez  
92 and Torres-Aleman, 2012; Saraiva et al., 2015), where insulin profoundly affects the survival  
93 and activity of neurons. For example, insulin receptor activation increases the proliferation of  
94 cultured OSNs *in vitro* (McEntire and Pixley, 2000), enhances the electrical activity of OSNs  
95 (Savigner et al., 2009), and prevents the apoptosis of adult OSNs following bulbectomy  
96 (Lacroix et al., 2011). Thus, insulin is an endogenous factor that strongly influences the cell  
97 function and homeostasis of OSNs in the OE. Although the expression of the insulin receptor in  
98 the OE has been described (Palouzier-Paulignan B et al., 2012), how insulin signaling in the OE  
99 affects the proliferation and incorporation of new OSNs within olfactory neuronal circuits are  
100 poorly understood.

101           The OE contains primarily mature OSNs with an average lifespan of around 90 days,  
102 such that the OSN regeneration rate is low under normal physiological conditions (Benson et  
103 al., 1984; Farbman et al., 1988; Gogos et al., 2000; Magklara and Lomvardas, 2013). However,  
104 OSNs are susceptible to injury and degeneration because the OE is directly exposed to  
105 environmental agents entering the nasal cavity. In such instances, progenitor cells promptly  
106 proliferate and differentiate into OSNs, which are subsequently incorporated into olfactory  
107 circuits (Goldberg and Barres, 2000). Thus, injury resets the stage for the differentiation of  
108 OSNs, providing an opportunity to study the kinetics of OSN differentiation and circuit  
109 integration.

110           To study the effects of insulin signaling on OSN regeneration, we experimentally  
111 induced diabetes mellitus in mice by injecting them with streptozotocin (STZ) to destroy the  
112 pancreatic islets of Langerhans (Furman, 2015) and reduce insulin levels. In addition, the  
113 olfactotoxic drug methimazole was administered to selectively injure OSNs without damaging  
114 the progenitor cells in the OE (Sakamoto et al., 2007). These methods enabled us to examine  
115 whether OSNs generated following injury are structurally and functionally incorporated into  
116 olfactory neuronal circuits in an insulin signal-dependent manner. We found that insulin  
117 signaling via the insulin receptor facilitated the regeneration of new OSNs, which were highly  
118 susceptible to insulin deprivation-induced apoptosis 8–13 days after the injury. These results  
119 indicate that during a critical stage newly generated OSNs are dependent on insulin signaling,  
120 and suggest that insulin signaling and the insulin receptor play a key role in the homeostatic  
121 regeneration of the OE following injury.

122

123

## 124 **Materials and Methods**

### 125 **Animals**

126 C57BL/6J (stock no. 000664) and M71-IRES-tauGFP (stock no. 006676) ([Bozza et al., 2002](#))



127 strains were purchased from the Jackson Laboratory. mOR-EG-IRES-tauGFP and  
128 I7-IRES-tauGFP mice were kindly provided by Dr. Touhara at University of Tokyo (Oka et al.,  
129 2006) and Drs. Mombaerts (Max Planck Research Unit for Neurogenetics) and Tom Bozza  
130 (Northwestern University) (Bozza et al., 2002). I7-IRES-tauGFP, M71-IRES-tauGFP, and  
131 mOR-EG-IRES-tauGFP strains are of a C57BL/6 congenic background. Male and female mice  
132 (3 weeks- to 6 months-old) were used (Table 1). Mice were maintained under a light and dark  
133 cycle (12:12 hours) in the University of Tokyo's and the Monell Chemical Senses Center's  
134 animal facilities at room temperature. All experiments were performed using procedures  
135 approved by the Experimental Animal Research Committee at the University of Tokyo and by  
136 the Monell Chemical Senses Center Institutional Animal Care and Use Committee.

137

#### 138 **Streptozotocin administration**

139 Pancreatic beta cells of mice were ablated by intraperitoneal (i.p.) injections of streptozotocin  
140 (STZ) (120 mg/kg of body weight; Sigma-Aldrich, S0130, St. Louis, MO, USA) dissolved in  
141 PBS (pH = 7.4) (Quality Biological, 119-069-491, Gaithersburg, MD, USA) or 0.9% NaCl  
142 solution (saline) for three consecutive days. Seven days after the first STZ injection, fasting  
143 blood glucose levels were measured with a glucose reader (Ascensia Diabetes Care, 7189,  
144 Parsippany-Troy Hills, NJ, USA) using blood obtained from the tail veins during the light  
145 phase. Mice were considered to be diabetic if fasting blood glucose levels were  $\geq 250$  mg/dl  
146 (Ishikawa et al., 2007).

147

#### 148 **Methimazole administration**

149 OSNs in control and diabetic mice (STZ mice) were ablated by i.p. injection of methimazole (75  
150 mg/kg, i.p.; Sigma-Aldrich, M8506) dissolved in saline. The mice were sacrificed after 3, 7, 14,  
151 or 28 days to observe regeneration of OE and projections of OMP<sup>+</sup> OSNs to OB. Projections of  
152 GFP<sup>+</sup> OSNs to OB in the I7-IRES-tauGFP, M71-IRES-tauGFP, and mOR-EG-IRES-tauGFP

153 mice were examined 45 days after methimazole injection.

154

#### 155 **Tissue preparation**

156 Mice were anesthetized with avertin (12.5 mg/ml; Sigma-Aldrich, T48402) or ketamine (60  
157 mg/kg; Sigma-Aldrich, K2753) and tissues were fixed by intracardiac perfusion with 4 %  
158 formaldehyde (PFA, Sigma-Aldrich, 158127) in PBS (pH = 7.4). The olfactory bulb (OB) and  
159 nose were dissected, postfixed with 4 % PFA in PBS for 2 h, soaked in 30 % sucrose in PBS,  
160 and embedded in O.C.T. compound. The noses were decalcified in 0.45 M EDTA solution (pH  
161 8.0) (Invitrogen, 15575-038, Carlsbad, CA, USA) before the treatment with 30 % sucrose in  
162 PBS. Coronal and/or sagittal sections of 12  $\mu$ m thickness were prepared using a cryostat  
163 (Thermo Scientific, Microm HM 500 OM, Waltham, MA, USA), mounted onto silane-coated  
164 slide glasses, and stored at -30 °C until use. Preparations including OE and OB were dissected  
165 from C57BL/6 mice, postfixed with the same fixative for 24 h, decalcified with 10 % EDTA  
166 solution (pH 7.0), and embedded in paraffin. Coronal sections (4  $\mu$ m thickness) were prepared  
167 using a microtome, collected onto silane-coated slide glasses, and stored at room temperature  
168 until use. Sections were stained with hematoxylin and eosin (HE, Muto Kagaku, 30002, Tokyo,  
169 Japan) and high-iron diamine-Alcian blue (Muto Kagaku, 40852, Tokyo, Japan) and  
170 immunohistochemically as described below.

171

#### 172 **Immunohistochemistry**

173 Paraffin-embedded sections were deparaffinized and autoclaved at 121°C for 20 min in Target  
174 Retrieval Solution (Dako Japan Inc., S1700, Kyoto, Japan). Frozen sections were briefly washed  
175 in PBS and incubated with 0.5 % SDS (v/v) in PBS for 15 min to retrieve antigen. Blocking was  
176 performed with 2 % bovine serum albumin (BSA, Sigma-Aldrich, A2153) in PBS with 0.1 %  
177 Triton X-100 (Sigma-Aldrich, 11332481001) for 10 min for the paraffin sections and with 5 %  
178 BSA in PBS with 0.3 % Triton for the frozen sections before overnight incubation with the

179 following primary antibodies at 4°C in a humidified chamber: anti-OMP (goat polyclonal,  
180 1:3,000; Wako Chemicals, 544-10001-WAKO, RRID: AB\_664696, Osaka, Japan), anti-GAP43  
181 (chicken polyclonal, 1:250; Thermo Fisher Scientific, PA5-95660, RRID: AB\_2807462,  
182 Waltham, MA, USA), anti-activated caspase-3 (rabbit polyclonal, 1:500; Cell Signaling  
183 Technology Inc., 9661, RRID: AB\_2341188, Danvers, MA, USA), anti-Ki67 (rabbit  
184 monoclonal, 1:300; Lab Vision, RM-9106-S1, RRID: AB\_149792, Värmdö, Sweden), and  
185 anti-c-Fos (rabbit IgG, 1:1,000; Santa Cruz Biotechnology Inc., 2250, RRID: AB\_2247211,  
186 Dallas, TX, USA). After the overnight incubation, tissues were washed with PBS and were  
187 incubated with the following secondary antibodies for 1 h at room temperature: donkey  
188 anti-goat Alexa Fluor 488 (1:100; Invitrogen, A32814, RRID: AB\_2762838), donkey  
189 anti-chicken Alexa Fluor 488 (1:250; Jackson ImmunoResearch Laboratories, 703-545-155,  
190 RRID: AB\_2340375, West Grove, PA, USA), and donkey anti-rabbit Alexa Fluor 594 (1:100;  
191 Invitrogen, A21207, RRID: AB\_141637). Nuclei were detected by  
192 4',6-diamidino-2-phenylindole (DAPI, 0.1 µg/ml; Life technologies, D3571, Carlsbad, CA,  
193 USA). The Histofine Simple Stain MAX-PO [R] secondary antibody system (Nichirei  
194 Biosciences, 414341F, RRID: AB\_2819094, Tokyo, Japan) was used to detect anti-Ki67.  
195 Stained and fluorescent images were acquired using a fluorescence microscope (Keyence,  
196 BZ-X710, Osaka, Japan) or a Leica TCS SP2 confocal microscope (Leica Microsystems, TCS  
197 SP2, Wetzlar, Germany).

198

### 199 **Histological quantification**

200 Histological evaluation in the OE was done for the hematoxylin and eosin (H-E) stained and  
201 immunohistochemical images of the nasal septum and the most dorsal parts of turbinate II from  
202 both the right and left nasal cavities. The thickness of the OE was measured with ImageJ  
203 software (National Institutes of Health, Bethesda, MD, USA) as the distance from the lamina  
204 propria to the surface. Cells, in H-E stained images, located between basal and apical most

205 areas, where immature and mature OSNs reside, were counted from at least two coronal sections  
206 500  $\mu\text{m}$  apart between the caudal and rostral regions of the OE from each of 3 mice to evaluate  
207 the regeneration of OSNs as described previously (Kikuta et al., 2015). The numbers of cells  
208 with immunoreactive signals for OMP, activated caspase-3, and Ki67 were also counted from at  
209 least two coronal sections 500  $\mu\text{m}$  apart ( $n = 3$  mice). A cell was considered positively  
210 immunostained when its staining exceeded two standard deviations (SDs) of the mean  
211 background intensity for the connective tissue under the lamina propria. The mean  $\pm$  SD of the  
212 counts of these cells was then calculated for each experimental group per 100  $\mu\text{m}$  length for  
213 OSNs and OMP-positive cells; the numbers of activated caspase-3- and Ki67-positive cells  
214 were similarly quantified per length. The sample size of sections from each mouse for the  
215 histological analysis was determined based on our previous study (Kikuta et al., 2015).

216 Whole glomerulus and OMP<sup>+</sup> areas in a given glomerulus were measured in the entire  
217 medial region from two or three coronal sections in the middle part along the anterior-posterior  
218 axis of the OB in STZ and control mice on days 14 and 28 after methimazole-induced injury.  
219 The total area of a glomerulus was delineated by the nuclei of surrounding periglomerular cells  
220 identified by DAPI staining. The OMP<sup>+</sup> area in a glomerulus was determined using ImageJ  
221 software and was defined as showing an OMP signals exceeding 2 SDs of the mean background  
222 intensity in the external plexiform layer of the OB. The percentage of the OMP-stained area was  
223 calculated within a glomerulus by dividing the area of the significantly OMP-stained area by the  
224 total area of the glomerulus (OMP-stained area/glomerular area  $\times$  100).

225 To analyze the amount of reinnervation, the area of the glomerulus was measured that  
226 contained GFP-labeled axons at the largest cross-section of a given glomerulus, when followed  
227 over consecutive sections. This was done for STZ and control mOR-EG-GFP mice 45 days after  
228 methimazole injection. The GFP fluorescence in a glomerulus was determined, and the intensity  
229 was calculated using Image J software. GFP-positive areas were defined as those with a GFP  
230 intensity greater than the mean minus 2 SDs, and the glomerular area was determined as the

231 area circled by periglomerular cells identified by DAPI staining. The ratio of the GFP-positive  
232 area to the corresponding total glomerulus area was calculated (GFP-positive area/each odorant  
233 receptor-specific glomerulus section with the largest area).

234

#### 235 ***In situ* hybridization**

236 *In situ* hybridization was carried out using digoxigenin-labeled antisense RNA of the insulin  
237 receptor gene (*Insr*) (Accession no. NM\_010568, n.t. 490-4608) as described previously  
238 (Ohmoto et al., 2008; Yamaguchi et al., 2014) or RNAscope<sup>®</sup> 2.5 HD Reagent Kit BROWN  
239 (Advanced Cell Diagnostics, 322371, Newark, CA, USA).

240 Digoxigenin-labeled antisense RNA was synthesized and used as a probe after  
241 fragmentation to approximately 150 bases under alkaline conditions. The PFA-fixed sections  
242 were treated with proteinase K (3 µg/ml, Thermo Fisher Scientific), postfixed with 4 % PFA,  
243 acetylated with acetic anhydride, and prehybridized with salmon testis DNA. After hybridized  
244 with the riboprobe for 40 h, sections were washed in 0.2x SSC (Invitrogen, 15-557).  
245 Prehybridization, hybridization, and wash were done at 65°C. Signals of hybridized probes were  
246 detected using alkaline phosphatase-conjugated anti-digoxigenin antibodies (Roche Diagnostics,  
247 11093274910, RRID: AB\_514497, Basel, Switzerland) followed by 4-nitro blue tetrazolium  
248 chloride/5-bromo-4-chloro-3-indolyl phosphate as a chromogenic substrate at room temperature  
249 overnight. RNAscope assay using Mm-Insr (Advanced Cell Diagnostics, 401011) or the  
250 negative control probe to *B. subtilis* dihydrodipicolinate reductase (DapB) (Advanced Cell  
251 Diagnostics, 310043) was also performed in accordance with the manufacturer's protocol.  
252 Stained images were acquired as described above.

253

#### 254 **Odor-induced c-Fos expression in the OB**

255 At twenty-eight days after methimazole injection, OE-ablated mice ( $n = 4-5$ /group) were  
256 housed individually, supplied with deodorized air through a charcoal filter, and exposed to odors

257 4 h after food pellets were removed. A mixture of odorants in three categories, aldehydes  
258 (propyl aldehyde, *N*-valeraldehyde, *N*-heptylaldehyde, benzaldehyde, and perilla aldehyde),  
259 lactones ( $\gamma$ -butyrolactone,  $\gamma$ -heptalactone,  $\delta$ -hexalactone,  $\delta$ -nonalactone, and  $\gamma$ -octalactone), and  
260 esters (amyl hexanoate, *b*- $\gamma$ -hexenyl acetate, terpinyl acetate, and isoamyl acetate) was diluted  
261 1/10 in mineral oil, and a cotton sheet soaked with 100  $\mu$ l of the diluted solution was placed in a  
262 dish in the cage twice for 1 h, with a 10 min interval between placements. After the second odor  
263 exposure, mice were anesthetized with ketamine (60 mg/kg) and their OBs were dissected as  
264 described above. *c*-Fos expression was detected immunohistochemically. Two or three coronal  
265 sections (4  $\mu$ m thick) from each OB at the middle part of the anterior-posterior axis were  
266 selected. The numbers of *c*-Fos-positive cells in the glomerular layer were counted in each of  
267 the four regions of the OB (the dorsolateral, dorsomedial, ventrolateral, and ventromedial parts)  
268 using images taken at 20 $\times$  magnification with a fluorescence microscope.

269

#### 270 **Electro-olfactogram recordings**

271 Electro-olfactogram (EOG) recordings were performed on STZ mice on day 90 after STZ  
272 administration and control mice on day 90 after saline administration without  
273 methimazole-induced injury, and 10-week-old control and STZ mice 14 and 28 days after  
274 methimazole-induced injury to evaluate the odor-induced response of the OE. The mice were  
275 euthanized with CO<sub>2</sub> and decapitated, and their heads were sagittally bisected at the center of  
276 the nasal septum. The septum was removed to expose the olfactory turbinates in the nasal  
277 cavity. The bisected heads were quickly transferred to a recording setup, where a stream of  
278 humidified air flowed (3 l/min) over the tissue.

279 Pentyl acetate (Sigma-Aldrich) was first dissolved in dimethyl sulfoxide (DMSO,  
280 Sigma-Aldrich, D8418) to make a 5 M stock solution, which was diluted in water to obtain  
281 odorant solutions ranging from  $1 \times 10^{-7}$  to  $10^{-1}$  M in 5 ml final volumes in sealed 50-ml glass  
282 bottles. As a control (0 M odorant), a solution of DMSO equivalent to the concentration in the

283  $10^{-1}$  M odorant solution was used. The headspace from each odorant solution was injected with  
284 a Picospritzer III (Parker Hannifin, Cleveland, OH, USA) into the air stream flowing over the  
285 OE to stimulate OSNs. The OE was exposed to each odorant solution and the odorant-induced  
286 responses were recorded in the following order;  $10^{-1}$  M,  $10^{-2}$  M,  $10^{-3}$  M,  $10^{-4}$  M,  $10^{-5}$  M,  $10^{-6}$   
287 M,  $10^{-7}$  M, 0 M,  $10^{-7}$  M,  $10^{-6}$  M,  $10^{-5}$  M,  $10^{-4}$  M,  $10^{-3}$  M,  $10^{-2}$  M, and  $10^{-1}$  M.

288 To record the EOGs, two electrodes were placed on the surfaces of turbinates II and IIB  
289 from either the left or right half of the head at similar positions in control and STZ mice  
290 (Barrios et al., 2014). The signals were recorded with two DP-301 amplifiers (Warner  
291 Instruments, Hamden, CT, USA), and the 1 kHz low-pass-filtered signal was digitized at 2 kHz  
292 with a Micro1401 mkII digitizer and Signal ver. 5.01 software (Cambridge Electronic Design,  
293 Cambridge, UK). The data were analyzed using Origin software ver. 8.5 (OriginLab,  
294 Northampton, MA, USA). The investigator was blinded to the mouse treatment for all EOG  
295 experiments until data analysis was completed. When the odorant-induced response showed  
296 more than 25% difference between the first  $10^{-1}$  M and the last  $10^{-1}$  M odorant exposure, the  
297 experiment was excluded from further analysis. All EOG recordings were performed during the  
298 light phase between 10 am and 5 pm.

299

### 300 **Odor-guided cookie search test**

301 Twenty-eight days after methimazole-induced injury, a cookie test was performed for 4  
302 consecutive days in control and STZ mice (7 mice/group) as previously reported (Stephan et al.,  
303 2011; Pietra et al., 2016). Starting at the same time of each day, the mice were food deprived for  
304 6 h with water access *ad libitum*. Each mouse was then transferred to a standard mouse cage  
305 (length, 24 cm; height, 12 cm, width, 15 cm), in which a 7–10 mm<sup>3</sup> piece of cookie (Oreo;  
306 Nabisco, East Hanover, NJ, USA) had been buried under fresh bedding at a 3 cm depth on trial  
307 days 1, 2, and 3; on trial day 4, the cookie was placed on the surface of the bedding. The cookie  
308 was placed in a randomly chosen corner of the cage in every trial to prevent mice from

309 predicting the position of the cookie on the basis of spatial information. After the mouse was  
310 placed in the cage, the latency to find the cookie was recorded, defined as the time until the  
311 mouse located the position of the cookie, dug the bedding, and bit into the cookie. The maximal  
312 time for this search task was set at 10 min. If the mouse failed to retrieve the cookie, it was  
313 exposed on the bedding for the mouse to eat. Once the trial was finished, each mouse was  
314 returned to its original cage. The test was conducted once each trial day. The order of tested  
315 mice was randomly chosen each day. Mice performed all the cookie search tests at room  
316 temperature during the light phase in the Monell Chemical Senses Center's animal facility.

317

#### 318 **Intraperitoneal and intranasal insulin administration**

319 For i.p. insulin injections, insulin detemir (100 units/ml; Novo Nordisk, Bagsvaerd, Denmark)  
320 was injected into STZ mice on day 1–13, 1–6, or 8–13 after methimazole injection (3 units/kg  
321 per administration; see Fig. 7A).

322 For intranasal administrations (Marks et al., 2009), Humulin R (100 units/ml; Lilly,  
323 Indianapolis, IN, USA) was applied to STZ mice with the same time course as for i.p.  
324 administration. For this, 30  $\mu$ l of insulin diluted 1/1, 1/2, or 1/3 with saline were applied to each  
325 nostril, and the insulin solution was drawn into both nasal cavities by the animal's natural  
326 inhalation. This was repeated three times each day at 9 am, 2 pm, and 7 pm for a total 90  $\mu$ l of  
327 insulin solution per day. To examine the effect of the nasal insulin administration on blood  
328 glucose levels, fasting blood glucose levels at 60 and 120 min after the administration of the  
329 1/1, 1/2, or 1/3 concentration of insulin (Fig. 7G) were measured with a glucose reader  
330 (Ascensia Diabetes Care).

331

#### 332 **Unilateral intranasal insulin receptor antagonist administration**

333 To evaluate the effect of blocking the insulin receptor in the nasal cavity, the insulin receptor  
334 antagonist, S961 (0.5  $\mu$ g/ $\mu$ l; Phoenix Pharmaceuticals, Burlingame, CA, USA) was unilaterally



335 applied to awake mOR-EG-GFP mice on day 8-13 after the methimazole injection. A volume of  
336 10  $\mu$ l of S961 was applied twice a day, resulting in a total 10  $\mu$ g of S961 application each day.  
337 In control mice, PBS was unilaterally applied with the same time course as for S961  
338 administration. The septal OE of three coronal sections from the caudal to rostral regions was  
339 analyzed for both the sides that received S961 or PBS and the non-applied control. To examine  
340 the effect of S961 on blood glucose levels, fasting blood glucose levels were measured at 120  
341 min after the administration (Fig. 8E) with a glucose reader (Ascensia Diabetes Care).

342

#### 343 **Statistical analysis**

344 All statistical analysis was conducted using OriginPro 2020 (OriginLab) or IBM SPSS statistics  
345 version 23 (IBM Japan, Tokyo, Japan). Statistical significance was tested by Mann-Whitney *U*  
346 test for comparison of two groups. Comparison among three or more groups was assessed by  
347 two-way repeated measures (RM) ANOVA for data with normality, by Friedman test for data  
348 that do not meet normality, when appropriate with Bonferroni's or Tukey's post-hoc test,  
349 Kruskal-Wallis *H* test followed by Mann-Whitney *U* test with Bonferroni correction, or  
350 Steel-Dwass test. Shapiro-Wilk test was conducted to check the data for normality. All data are  
351 presented as the means  $\pm$  SDs. A *p* value of  $< 0.05$  was considered to be statistically significant  
352 ( $*p < 0.05$ ,  $**p < 0.01$ ,  $***p < 0.001$ ).

353

354

## 355 **Results**

### 356 **Expression of the *Insr* gene in the OE**

357 First, we examined in which cell type the *Insr* gene is expressed in the OE by performing *in situ*  
358 hybridization on an OE of a control mice using digoxigenin-labeled antisense RNA of *Insr* (Fig.  
359 1A) and RNAscope assay against *Insr* (Fig. 1B) (also see Fig. 8A for an RNAscope assay  
360 against *Insr*). Fig. 1A shows a representative image of a coronal OE section at low (left panel)

361 and high magnification (middle and right two panels). Fig. 1A,B (left panels) shows that the  
362 mRNA signal for *Insr* is visible in the turbinates, as well as in the nasal septum. Fig. 1A (middle  
363 panel) shows that the *in situ* signal is observed in the apical and basolateral layers of the OE  
364 (see also Fig. 8A), where supporting cells and immature OSNs are located. Also note the  
365 somewhat non-homogeneous staining, with some areas showing higher levels of *Insr* expression  
366 compared with others (right panels in Fig. 1A,B).

367

### 368 **Decreased insulin signaling for 90 days does not alter OE structure**

369 To examine the effect of insulin signaling on tissue homeostasis in uninjured OE, we generated  
370 diabetic mice using i.p. injections of STZ (Fig. 1C). On average ( $\pm$  SD), both fasted and fed  
371 blood glucose levels in mice at 10 days after STZ treatment were higher [fasted,  $343 \pm 48$  mg/dl  
372 (23 male mice), fed,  $355 \pm 51$  mg/dl (15 male mice),  $p = 0.769$ ; Steel-Dwass test] than before  
373 STZ administration [fasted,  $94 \pm 12$  mg/dl (11 male mice); fed,  $100 \pm 16$  mg/dl (12 male mice),  
374  $p = 0.855$ ; Steel-Dwass test] (pre-STZ, fasted vs. post-STZ, fasted,  $p < 0.001$ ; pre-STZ, fed vs.  
375 post-STZ, fed,  $p < 0.001$ , Steel-Dwass test) (Fig. 1D). We did not detect differences in the body  
376 weights of the mice before and after STZ administration [ $22.5 \pm 1.1$  g (20 male mice) vs.  $21.5 \pm$   
377  $2.1$  g (12 male mice), respectively,  $p = 0.080$ , Mann-Whitney *U* test] (Fig. 1E).

378 We next examined histological changes in the OEs of STZ mice [fixation on day 28  
379 (STZ-d28) and 90 (STZ-d90) after STZ administration] and control mice [fixation on day 28  
380 (saline-d28) after saline administration] (Fig. 1F). Fig. 1G,H shows representative coronal  
381 sections of OEs stained with hematoxylin (left and upper right) and immunostained with an  
382 anti-OMP antibody to identify mature OSNs (lower right) in STZ-d28 and STZ-d90 mice.

383 The OE thickness and the number of OSNs in STZ-d90 mice did not differ from those  
384 in STZ-d28 and saline-d28 mice (OE thickness: two-way RM ANOVA, Day:  $F(1, 15) = 0.17$ ,  $p$   
385  $= 0.682$ ; Treatment:  $F(1, 15) = 4.21$ ,  $p = 0.058$ ; Interaction:  $F(1, 15)$ ,  $p = 0.800$ ; number of  
386 OSNs: two-way RM ANOVA, Day:  $F(1, 15)$ ,  $p = 0.725$ ; Treatment:  $F(1, 15)$ ,  $p = 0.913$ ;

387 Interaction:  $F(1, 15), p = 0.595$ ) (Fig. 1I,J). To examine whether odorant-induced responses in  
388 the OE were changed in STZ-d90 and saline-d90 mice, EOG recordings were performed ( $n = 6$   
389 mice/group) (Fig. 1K,L). Consistent with the histological results, EOG response amplitudes to  
390 the odorant pentyl acetate were not significantly different between both groups of mice at each  
391 odorant concentration (two-way RM ANOVA, odor concentration:  $F(1, 5) = 181.32, p < 0.001$ ;  
392 STZ treatment:  $F(1, 5) = 1.16, p = 0.330$ ; Interaction:  $F(1, 5) = 0.950, p = 0.374$ ) (Fig. 1L).  
393 These results suggest that decreased insulin signaling alone for 90 days does not induce  
394 histological changes and reduce odorant-induced responses in uninjured OE.

395

#### 396 **Insulin signaling is required for the replacement of functional OSNs after OE injury**

397 We next investigated whether decreased insulin signaling affects the incorporation of new  
398 neurons following OE injury. Methimazole, an olfactotoxic drug, activates an apoptotic cascade  
399 in OSNs throughout the OE (Brittebo, 1995; Sakamoto et al., 2007). The lost OSNs are replaced  
400 by new OSNs from proliferating progenitor cells, such that the OE returns to its preinjury state  
401 after one month (Schwob, 2002; Kikuta et al., 2015). To examine whether insulin signaling  
402 contributes to this recovery, we assessed histological changes in the OE 3, 7, 14, and 28 days  
403 after methimazole-induced injury in control and STZ mice (Fig. 2A). The OEs in control and  
404 STZ mice recovered similarly during the first 7 days after methimazole-induced injury, and no  
405 significant differences in the thicknesses of the OEs or the numbers of OSNs were observed  
406 (OE thickness,  $p = 1.000$ ; numbers of OSNs,  $p = 1.000$ ; two-way RM ANOVA with  
407 Bonferroni's post-hoc test) (Fig. 2B–D). The OE thickness and number of OSNs in control mice  
408 gradually increased to match the levels observed with saline administration on day 28  
409 (control-d28 ( $n = 3$  mice) vs. saline-d28 ( $n = 3$  mice): OE thickness,  $p = 0.702$ ; numbers of  
410 OSNs,  $p = 0.796$ ; Mann-Whitney  $U$  tests) (Fig. 2C,D). By comparison, the recovery in STZ  
411 mice was significantly suppressed [control ( $n = 3$  mice) vs. STZ ( $n = 3$  mice): OE thickness: day  
412 14,  $p = 0.005$ , day 28,  $p = 0.003$ ; numbers of OSNs: day 14,  $p < 0.001$ , day 28,  $p < 0.001$ ;

413 two-way RM ANOVA with Bonferroni's post-hoc test] (Fig. 2B–D).

414 To examine whether the impaired regeneration in STZ mice is also accompanied by  
415 reduced numbers of mature OSNs, we quantified the number of OMP-immunostained OSNs in  
416 the OE. Fig. 2E shows representative pictures of nasal septum sections stained with anti-OMP  
417 antibodies. OMP-positive cells were not detectable 7 days after injury, but emerged after 14  
418 days in both control and STZ mice (Fig. 2E); however, there were significantly fewer  
419 OMP-positive cells in STZ mice than in control mice (control-d14 ( $n = 3$  mice) vs. STZ-d14 ( $n$   
420  $= 3$  mice):  $p < 0.001$ ; two-way RM ANOVA with Bonferroni's post-hoc test) (Fig. 2F). On day  
421 28, the number of OMP-positive cells in control mice matched the number in saline-treated  
422 (uninjured) mice (control-d28 ( $n = 3$  mice), vs. saline-d28 ( $n = 2$  mice),  $p = 0.966$ ;  
423 Mann-Whitney  $U$  test) (Fig. 2F), whereas the number in STZ mice was significantly lower than  
424 in control mice (control-d28 vs. STZ-d28,  $p < 0.001$ ; two-way RM ANOVA with Bonferroni's  
425 post-hoc test) (Fig. 2F). These results indicate that decreased insulin signaling results in  
426 incomplete recovery of the OE with fewer newly generated OSNs at 14 and 28 days after injury.

427 We performed EOG recordings in control and STZ mice to examine whether the  
428 incomplete recovery of the OE after STZ administration on days 14 and 28 after injury was  
429 accompanied by decreased odor-induced responses ( $n = 6$  mice/group) (Fig. 3). We observed  
430 similar response kinetics in the EOG recordings from control and STZ mice (Fig. 3A, C).  
431 However, the amplitudes in response to higher odorant concentrations in STZ mice were  
432 significantly lower than those in control mice both at day 14 and at day 28 (day 14, pentyl  
433 acetate:  $10^{-1}$  M odorant solution,  $p < 0.001$ ;  $10^{-2}$  M,  $p < 0.001$ ; day 28, pentyl acetate:  $10^{-1}$  M  
434 odorant solution,  $p < 0.001$ ;  $10^{-2}$  M,  $p < 0.001$ ;  $10^{-3}$  M,  $p = 0.047$ ; two-way RM ANOVA with  
435 Bonferroni's post-hoc test) (Fig. 3B,D). These results suggest that an incomplete recovery of the  
436 OE in STZ mice is reflected in decreased odor-evoked responses.

437

438 **Reduced axonal projections of new OSNs to glomeruli and decreased glomerular**

439 **responses to odorants in STZ mice**

440 Newly generated OSNs extend their axons to the glomeruli in the OB and form excitatory  
441 synapses on the dendrites of interneurons and OB projection neurons within the glomerular  
442 structure. As OMP is expressed throughout the axons and axon terminals of mature OSNs (Mori  
443 and Sakano, 2011), we measured the OMP-stained areas within individual glomeruli in control  
444 and STZ mice to examine whether decreased insulin signaling affects the axonal projections of  
445 newly generated OSNs after OE injury. Fig. 4A shows representative images of OMP  
446 immunostaining in the medial areas of the OB. The axonal target glomeruli in these areas were  
447 preferentially selected because they receive projections from the medial part of the OE,  
448 including the nasal septum, which we examined for regeneration. Consistent with the results of  
449 OMP-positive OSNs in the OE, the OMP-stained areas in the OB on days 14 and 28 postinjury  
450 were significantly smaller in STZ mice than in control mice (control-d14 ( $n = 3$  mice) vs.  
451 STZ-d14 ( $n = 4$  mice),  $p < 0.001$ ; control-d28 ( $n = 5$  mice) vs. STZ-d28 ( $n = 4$  mice),  $p < 0.001$ ;  
452 Friedman test followed by Mann-Whitney  $U$  test with Bonferroni correction) (Fig. 4B). These  
453 results suggest that decreased insulin signaling results in axonal projections from fewer newly  
454 generated OSNs.

455 We next investigated whether odorant receptor-specific axonal targeting to specific  
456 glomeruli was disturbed in mOR-EG-GFP (as well as I7 and M71) mice (Fig. 4C). Very little  
457 axonal reinnervation was observed at day 30 (data not shown). Fig. 4D shows representative  
458 images of GFP-expressing glomeruli from control and STZ-treated mOR-EG-GFP mice 45 days  
459 after methimazole injection. Whereas axon terminals of OSNs abundantly spread laterally  
460 within a glomerulus from control mice, the terminals showed reduced innervation in STZ  
461 (mOR-EG-GFP) mice (Fig. 4D). Quantitative analyses of GFP-positive areas revealed that the  
462 GFP-positive area was significantly smaller in STZ mOR-EG-GFP mice than in control mice at  
463 45 days after injury (control ( $n = 6$  mice), STZ ( $n = 4$  mice);  $p < 0.001$ ; Mann-Whitney  $U$  test)  
464 (Fig. 4E). However, the area of GFP-expressing glomeruli was not significantly different

465 between the control and STZ mOR-EG-GFP mice ( $p = 0.140$ ; Mann-Whitney  $U$  test) (Fig. 4F),  
466 suggesting that the reduced GFP-expressing area was a result of impaired axonal targeting.  
467 However, incomplete regeneration 45 days after injury was observed in OSNs from both control  
468 and STZ I7 and M71 mice (data not shown). Although we cannot rule out the possibility that the  
469 time courses for replacing neurons following injury differ for individual odorant receptors, the  
470 impaired replacement of axon terminals within glomeruli in STZ (mOR-EG-GFP) mice is  
471 consistent with the overall impaired recovery of OMP-positive axon terminals within the OB  
472 observed in the STZ-treated C57BL/6 mice.

473 To determine whether the reduced axonal reinnervation was accompanied by a  
474 decrease in the glomerular responses to odorants, we quantified c-Fos (a neural activity marker)  
475 induction in cells throughout the OB. At 28 days after methimazole-induced injury, control and  
476 STZ mice were exposed to odorants (aldehydes, lactones, and esters) selected for their  
477 activation of the dorsal and ventral OB (Fig. 4G). A schematic of a coronal section through the  
478 OB (Fig. 4H, left) displays the four quadrants: ventromedial (v-m), ventrolateral (v-l),  
479 dorsomedial (d-m), and dorsolateral (d-l). Representative coronal sections of the d-m area  
480 stained by the anti-c-Fos antibody (red) and DAPI (blue) are shown for control and STZ mice in  
481 Fig. 4H (right). STZ mice had significantly fewer c-Fos-positive cells in each quadrant of the  
482 OB than did control mice [control ( $n = 4$  mice) vs. STZ ( $n = 5$  mice); d-l,  $p = 0.005$ ; d-m,  $p =$   
483  $0.002$ ; v-l,  $p = 0.007$ ; v-m,  $p = 0.008$ ; Mann-Whitney  $U$  test; Fig. 4I]. Together, these results  
484 suggest that the loss of insulin signaling during the recovery from OE injury impairs glomerular  
485 olfactory responses because of the incomplete incorporation of new OSNs into olfactory neural  
486 circuits.

487

#### 488 **STZ mice exhibit impaired detection of the odor of buried food**

489 To determine whether the reduced olfactory signaling in the OE and OB in STZ mice was  
490 accompanied by behavioral deficits, mice performed an odor-guided food-seeking paradigm 28

491 days after OE injury, in which their latency to locate a cookie buried in the bedding was  
492 measured (Fig. 5A,B). On trial day 1, five of seven STZ mice failed to locate the cookie within  
493 the 10 min test time, whereas only one of seven control mice failed this test. On average, STZ  
494 mice were significantly slower in locating the cookie ( $n = 7$  mice/group;  $p = 0.001$ , two-way  
495 RM ANOVA with Tukey post-hoc test) (Fig. 5C). The control and STZ mice began to locate the  
496 cookie faster on subsequent trial days, but the STZ mice continued to display longer latencies  
497 than the control mice (trial day 2,  $p = 0.008$ ; trial day 3,  $p = 0.004$ , two-way RM ANOVA with  
498 Tukey post-hoc test) (Fig. 5C). On trial day 4, the cookie was not buried and so could be  
499 detected visually by the mice. In this trial, STZ mice performed the task as quickly as did the  
500 control mice ( $p = 0.954$ , two-way RM ANOVA with Tukey post-hoc test) (Fig. 5C). This  
501 indicates that no gross motor or motivational deficits account for the observed difference when  
502 the cookie was buried. These results suggest that STZ mice have functional deficits in  
503 recognizing and/or locating the source of some odors.

504

505 **Decreased insulin signaling does not alter proliferation but increases apoptosis in**  
506 **immature neurons**

507 To examine the mechanisms underlying the incomplete replacement of new OSNs after injury,  
508 we examined the proliferation and induction of apoptosis of OE cells via immunostaining for  
509 Ki67 and activated caspase-3, respectively, 3, 7, 14, and 28 days after injury in control and STZ  
510 mice. The representative images of nasal septa in Fig. 6A show that the number of Ki67-positive  
511 cells began to gradually decrease after the injury (Fig. 6A). However, the numbers of  
512 Ki67-positive cells did not differ between control and STZ mice at any time point after injury ( $n$   
513 = 2–3 mice/group; day 3,  $p = 1.000$ ; day 7,  $p = 1.000$ ; day 14,  $p = 1.000$ ; day 28,  $p = 1.000$ ;  
514 two-way RM ANOVA with Bonferroni's post-hoc test) (Fig. 6B). By contrast, representative  
515 images of activated caspase-3 immunostaining revealed the presence of more apoptotic cells in  
516 STZ than in control mice (Fig. 6C). Very few activated caspase-3-positive cells were detected in

517 the nasal septa of the OEs from STZ and control mice 7 days after injury ( $n = 3$  mice/group;  $p =$   
518 1.000; two-way RM ANOVA with Bonferroni's post-hoc test), while the numbers of apoptotic  
519 cells were significantly higher in STZ mice at the later time points (day 14,  $p < 0.001$ ; day 28,  $p$   
520  $< 0.001$ ; two-way RM ANOVA with Bonferroni correction) (Fig. 6C,D). The apoptosis of cells  
521 in STZ mice was greatest on day 14 (day 7 vs. day 14,  $p < 0.001$ ; day 14 vs. day 28,  $p < 0.001$ ;  
522 day 7 vs. day 28,  $p < 0.001$ ; two-way RM ANOVA with Bonferroni correction) (Fig. 6D). To  
523 examine whether these apoptotic cells were mature or immature OSNs, we performed double  
524 immunostaining for activated caspase-3 and OMP or GAP43 (Fig. 6E). The majority of the  
525 activated caspase-3-positive cells were not co-labeled with OMP [91/105 (87%),  $n = 3$  mice;  
526 white arrowheads in Fig. 6E, top] but instead with GAP43 [71/85 (84%),  $n = 3$  mice; white  
527 arrowheads in Fig. 6E, bottom], indicating that nearly all apoptotic cells were immature OSNs.  
528 Altogether, these results suggest that the incomplete recovery of OSNs in the OEs of mice with  
529 decreased insulin signaling was not a result of reduced proliferation of basal progenitor cells but  
530 rather an increase in the apoptosis of OSNs before they reach maturity, which varied between 7  
531 and 28 days after injury.

532

### 533 **Period of susceptibility for insulin signal-dependent survival or death of new OSNs**

534 We previously reported that new OSNs have a specific time window for sensory  
535 input-dependent survival or death and are more susceptible to apoptosis when they become  
536 OMP-positive mature cells (Kikuta et al., 2015). We hypothesized that this enhanced  
537 susceptibility would also occur with decreased insulin signaling. To identify a period during  
538 which new OSNs may be highly dependent on insulin signaling, we investigated the  
539 replacement of new OSNs in response to insulin administration at different times after injury.  
540 We focused on the first 14 days after injury, because it was during this period that we observed  
541 the emergence of OMP-positive neurons.

542 In this experiment, insulin was administered to STZ mice via i.p. injections throughout



543 the 14-day postinjury period or during the first or second half of this period (Fig. 7A). Fig. 7B  
544 shows representative coronal sections of the nasal septa from control and STZ mice 14 days  
545 after injury. The OEs of mice that received insulin on days 1–6 were significantly thinner, with  
546 fewer OSNs and OMP-positive cells, than the OEs of mice that received insulin on days 1–13  
547 and days 8–13 ( $n = 3\text{--}4$  mice/group; OE thickness, d1–13 vs. d1–6,  $p < 0.001$ ; d1–6 vs. d8–13,  
548  $p < 0.001$ ; number of OSNs, d1–13 vs. d1–6,  $p < 0.001$ ; d1–6 vs. d8–13,  $p < 0.001$ ; number of  
549 OMP-positive cells, d1–13 vs. d1–6,  $p < 0.001$ ; d1–6 vs. d8–13,  $p < 0.001$ ; Kruskal-Wallis test  
550 followed by Mann-Whitney  $U$  test with Bonferroni correction) (Fig. 7C–E). By contrast, there  
551 were no differences in these parameters between mice receiving insulin on days 8–13 and those  
552 receiving insulin for the entire period ( $n = 3$  mice/group; OE thickness,  $p = 0.966$ ; number of  
553 OSNs,  $p = 1.000$ ; number of OMP-positive cells,  $p = 1.000$ ; Kruskal-Wallis test followed by  
554 Mann-Whitney  $U$  test with Bonferroni correction) (Fig. 7C–E). These results suggest that newly  
555 generated OSNs are highly dependent on insulin signaling 8–13 days post injury.

556           Blood glucose levels are inevitably altered by i.p. insulin administration, which may  
557 affect the regeneration of the OE after injury via increased superoxide production (Giacco and  
558 Brownlee, 2010). Thus, it remains unclear whether the impaired OE regeneration in STZ mice  
559 was influenced by the loss of insulin signaling in the OE or by the high blood glucose levels  
560 caused by hypoinsulinemia. To investigate this, we examined the effects of intranasally applied  
561 insulin on OE regeneration in STZ mice (Fig. 7F). We first determined which insulin  
562 concentration did not affect blood glucose levels. Fig. 7G shows blood glucose levels before  
563 (pre-ad) and at 60 and 120 min after intranasal administration of insulin at three concentrations.  
564 An insulin solution diluted 3 $\times$  with saline did not alter blood glucose levels after 60 or 120 min  
565 ( $n = 7$  male mice; pre-ad vs. 60 min,  $p = 0.973$ ; pre-ad vs. 120 min,  $p = 0.928$ ; Steel test) (Fig.  
566 7G), whereas the higher concentrations significantly reduced the blood glucose levels (no  
567 dilution,  $n = 7$  male mice: pre-ad vs. 60 min,  $p = 0.044$ ; pre-ad vs. 120 min,  $p = 0.046$ ; 2 $\times$   
568 dilution,  $n = 8$  male mice: pre-ad vs. 60 min,  $p = 0.002$ ; pre-ad vs. 120 min,  $p = 0.003$ ; Steel

569 test) (Fig. 7G). Thus, we used the 3× diluted insulin solution to examine the effect of insulin on  
570 OE regeneration in the absence of altered blood glucose levels. Fig. 7H shows representative  
571 coronal sections of nasal septa from STZ mice for each treatment regime 14 days after injury.  
572 Consistent with the results from i.p. insulin administration, the number of OMP-positive OSNs  
573 was significantly lower only in the group receiving intranasal insulin only on days 1–6 ( $n = 3$   
574 mice/group; d1–13 vs. d1–6,  $p < 0.001$ ; d1–6 vs. d8–13,  $p < 0.001$ ; d1–13 vs. d8–13,  $p = 1.000$ ;  
575 Kruskal-Wallis test followed by Mann-Whitney  $U$  test with Bonferroni correction) (Fig. 7I).  
576 These results indicate that the absence of insulin signaling 8–13 days after injury impairs the  
577 recovery of the OE. Thus, insulin signaling during this period is involved in the regeneration of  
578 the OE.

579

580 **Upregulation of insulin signaling during the specific period is required for OSN**  
581 **maturation**

582 Fig. 7 shows that insulin-dependency is increased on days 8–13 post-injury, implying  
583 upregulation of *Insr* expression during this period. To examine whether the level of *Insr*  
584 expression is changed between uninjured OE and the OE at day 14 following injury, an  
585 RNAscope assay was carried out using an *Insr* probe. Fig. 8A,B show representative images of  
586 the uninjured OE and OB and the OE and OB at day 14 after injury, with the *Insr* mRNA signal  
587 appearing as small brown dots. Similar to *in situ* hybridization results in Fig. 1A,B, the  
588 RNAscope signals are observed sparsely in the layer of supporting cells and OSNs of the  
589 uninjured OE (Fig. 8A left panel). Overall, the signal intensity is relatively weak. However, Fig.  
590 8A (right panel, day 14 following injury) shows a much higher number of dots both in  
591 supporting cell and OSN layers, while the mRNA signal intensity appears similar between the  
592 uninjured OB and the OB at day 14 following injury (Fig. 8B). No signals were detected by the  
593 negative control probe B. subtilis dihydrodipicolinate reductase (DapB) in the OE of control  
594 mice (data not shown). These results suggest that *Insr* expression is highly upregulated in the

595 OE at day 14 post-injury, when the delay of OE regeneration after injury had already begun in  
596 STZ-mice after day 7 post-injury (Fig. 2B–F, Fig. 3A,B, Fig. 4A,B, Fig. 6C–E).

597         Given these results, we next applied intranasally the insulin receptor antagonist, S961  
598 to assess the effect of blocking insulin signaling on OE regeneration following injury. In this  
599 experiment, S961 was applied on days 8–13 post-injury twice daily and intranasal PBS  
600 application was performed similarly with control mice (Fig. 8C). To compare the effect of  
601 blocking insulin signaling within a mouse, S961 or PBS was unilaterally applied (Fig. 8D). We  
602 also monitored the effect of intranasal S961 application (0.5  $\mu\text{g}/\mu\text{l}$ , 10 $\mu\text{l}$ ) on blood glucose  
603 level. Fig. 8E shows the blood glucose values before and at 120 min after intranasal S961  
604 application. No obvious increase of blood glucose by intranasal S961 application was observed  
605 ( $n = 4$  mice; pre-S961 vs. 120 min) (Fig. 8E), suggesting that this treatment did not alter  
606 systemic glucose levels. Fig. 8F shows the representative images of coronal sections of the  
607 nasal septum on day 14 post-injury in control mice treated with PBS or S961. PBS application  
608 did not cause any significant decreases of the OE thickness and the number of OSNs and  
609 OMP-positive OSNs compared with those in the OE of the control side ( $n = 3$  mice/group; OE  
610 thickness,  $p = 1.000$ ; number of OSNs,  $p = 1.000$ ; number of OMP-positive cells,  $p = 1.000$ ;  
611 Kruskal-Wallis test followed by Mann-Whitney  $U$  test with Bonferroni correction) (Fig. 8G–I).  
612 By contrast, supporting the results from intranasal insulin application (Fig. 7H,I), the OE  
613 thickness was significantly thinner and the number of OSNs and OMP-positive OSNs were  
614 significantly smaller in the OE that received S961 compared with those in the OE of the control  
615 sides ( $n = 3$  mice/group; OE thickness, PBS-C vs. S961,  $p = 0.009$ ; S961 vs. S961-C,  $p = 0.002$ ;  
616 number of OSNs, PBS-C vs. S961,  $p = 0.009$ ; S961 vs. S961-C,  $p = 0.010$ ; number of  
617 OMP-positive cells, PBS-C vs. S961,  $p = 0.002$ ; S961 vs. S961-C,  $p = 0.002$ ; Kruskal-Wallis  
618 test followed by Mann-Whitney  $U$  test with Bonferroni correction) (Fig. 8G–I). Taken together,  
619 these results suggest that insulin signaling via the insulin receptor is required for OSN  
620 maturation at days 8–13 post-injury, when *Insr* expression is highly upregulated in the OE.

621

622 **Insulin signal promotes the OE regeneration following injury when *Insr* expression is**  
623 **highly upregulated**

624 If insulin signaling is important for the maturation and survival of newly-generated OSNs  
625 following injury, when *Insr* expression is highly upregulated, an insulin-enriched environment  
626 could facilitate their maturation even in non-diabetic mice. To test this hypothesis, we first  
627 examined the effect of intranasal insulin application on OSN regeneration after injury (in  
628 non-diabetic mice). Insulin was applied to a single naris on days 1–6 and days 1–13 postinjury  
629 three times daily to compare the effect of insulin signaling between the two sides of the nose  
630 (Fig. 9A). Representative images of the nasal septum stained with anti-OMP antibody for both  
631 groups are shown in Fig. 9B. In the group subjected to insulin application 1 – 6 days after injury,  
632 OMP-positive cells were not identified at this stage in both the application and contralateral  
633 sides. At 14 days after injury, newly generated OSNs began to mature, but intranasal application  
634 during 1–13 days after injury induced a significant increase of OMP-positive cells on the  
635 application side compared with the contralateral side ( $n = 4$  mice; number of OMP-positive  
636 cells,  $p < 0.001$ ; Mann-Whitney U test) (Fig. 9C). These results indicate that insulin application  
637 1–13 days after injury increases and further facilitates the maturation of newly generated OSNs  
638 even in non-diabetic mice, leading to faster functional recovery of the OE. To determine  
639 whether insulin signaling during the period of high *Insr* expression would be critical for the  
640 promotion of functional recovery of the OE following injury, we examined the effect of insulin  
641 application on OSN regeneration in an early period (d1–6 insulin after injury) and a late period  
642 (d8–13 insulin after injury). The details of this experiment are described in Fig. 9D. The timing  
643 of the insulin application differed between the two groups such that one group of mice received  
644 insulin on 1–6 days after injury (Fig. 9D, left) and the other group received the insulin  
645 application on 8–13 days after injury (Fig. 9D, right). Representative coronal sections of the  
646 nasal septum and concha bullosa for both groups are shown in Fig. 9E.

647           In the group subjected to insulin application 1–6 days after injury, the number of  
648 OMP-positive cells for both sides did not significantly differ ( $n = 4$  mice; number of  
649 OMP-positive cells,  $p = 1.000$ ; two-way RM ANOVA with Bonferroni's post-hoc test) (Fig. 9F).  
650 By contrast, insulin application during days 8–13 caused a significant increase of the  
651 OMP-positive cells on the application side compared with those on the contralateral side ( $n = 4$   
652 mice; number of OMP-positive cells,  $p = 0.003$ ; two-way RM ANOVA with Bonferroni's  
653 post-hoc test) (Fig. 9F). Furthermore insulin application during this period caused a significant  
654 increase of the OMP-positive cells on the application side compared with those on the  
655 application side during days 1–6 after injury ( $p = 0.003$ ; two-way RM ANOVA with  
656 Bonferroni's post-hoc test) (Fig. 9F). These results indicate that insulin signaling during the  
657 period when *Insr* is highly expressed is a primary factor to facilitate the incorporation of newly  
658 generated OSNs into neural circuits.

659

660

## 661 **Discussion**

662 This study demonstrates that the insulin receptor is required for regeneration following injury  
663 and that its expression in the OE is dynamically regulated depending on the physiological or  
664 regenerative condition of the OE. Overall moderate and locally restricted signals in the  
665 uninjured OE for *Insr* (Figs 1A,B, 8A) hint at local regeneration as part of the normal turnover of  
666 cells in the OE. And high expression levels of *Insr* in the OE on day 14 after the total  
667 degeneration of OSNs and supporting cells induced by methimazole support the requirement of  
668 the insulin receptor in the regeneration process (Fig. 8A). Intranasal insulin application directly  
669 to the OE improves the maturation and survival of new neurons after methimazole-induced  
670 injury (Fig. 7H,I, Fig. 8F–I, Fig. 9). Insulin is a growth-stimulating hormone produced by  
671 pancreatic beta cells (Baura et al., 1993; Banks, 2004; Laron, 2009; Fernandez and  
672 Torres-Aleman, 2012) and perhaps also in the brain (Gray et al., 2014). Its effects parallel those

673 of insulin-like growth factors IGF-1 and IGF-2. This is due not only to the structural similarity  
674 between insulin and the IGFs, but also to the high degree of homology between the insulin  
675 receptor and the IGF receptors. However insulin binds to insulin receptor with a 100-1000-fold  
676 higher affinity for the other receptors ([Fernandez and Torres-Aleman, 2012](#)). Further, in contrast  
677 with many peripheral tissues, brain insulin binding and insulin receptors levels are not  
678 upregulated during experimental DM ([Pacold and Blackard, 1979](#); [Sechi et al., 1992](#); [Pezzino et  
679 al., 1996](#)). After injury to the OE in non-diabetic mice, we found that *Insr* expression was highly  
680 upregulated in the whole OE layer (Fig. 8A). Furthermore, a decreased level of circulating insulin  
681 and diminished insulin in diabetic mice impair the regeneration of the OE, suggesting that,  
682 indeed, insulin is required.

683 Under our control conditions (i.e., without OE injury), the OE contained primarily  
684 mature OSNs. An STZ-induced decrease in insulin did not affect the structure and  
685 odorant-induced responses of the OE (Figs 1, 10A). Because *Insr* expression is moderate  
686 especially in mature OSNs of the uninjured OE (Figs 1A,B, 8A) ([Saraiva et al., 2015](#)), the  
687 dependency on insulin may not be large, resulting in few effects on the OE in STZ mice. After  
688 methimazole-induced injury, however, we observed the generation of new OSNs and their  
689 gradual incorporation into neural circuits (Figs 2B,E, 4A,D, 10B). The decreased insulin in STZ  
690 mice significantly affected the regeneration process 8 – 13 days after the injury. Specifically,  
691 hypoinsulinemia reduced the thickness of the OE, the number of OSNs, and the number of  
692 OMP-positive cells (Figs 2B–F, 10B). Consistent with these findings, we observed increased  
693 apoptosis but unchanged proliferation of immature OSNs in STZ mice during this period (Fig.  
694 6). The nasally-applied insulin during the regeneration process compensated for and rescued an  
695 incomplete repair of the OE in STZ mice (Fig. 7) and promoted the OE repair even in control,  
696 non-diabetic mice (Fig. 9), while the block of insulin receptor-mediated signaling impaired the  
697 OE repair in non-diabetic mice (Fig. 8). These results indicate that the survival of new neurons  
698 requires insulin and the insulin receptor, and their survival strongly influences the regeneration

699 of the OE.

700

701 **Possible mechanisms for incomplete replacement of new OSNs in the STZ mice**

702 Insulin in the brain acts as a neuromodulator influencing synaptic plasticity, dendritic  
703 outgrowth, and neurotransmitter release, while also promoting neuronal survival and  
704 proliferation (Bruning et al., 2000; Plum et al., 2005; Mielke et al., 2006; Valenciano et al.,  
705 2006). Thus, insulin is likely strongly involved in the maintenance of neural circuit functions.  
706 Activation of the insulin receptor involves intracellular downstream cascades, including  
707 phosphoinositide 3-kinase–AKT–forkhead box protein O and RAS-MAPK pathways. These  
708 pathways modulate gene transcription and activate myriads of downstream kinase-phosphatase  
709 branches that ultimately affect key cellular processes, such as protein synthesis, autophagy,  
710 apoptosis, and resistance to oxidative stress (Fernandez and Torres-Aleman, 2012).  
711 Furthermore, STZ-treated rats exhibit reduced expression of glycogen synthase kinase 3 $\beta$  in the  
712 brain (Jing et al., 2017), which activates the Wnt signaling pathway that reduces synaptic  
713 GABA and glutamate transporters important for the maintenance of synapses (Kuwabara et al.,  
714 2009). Therefore, decreased insulin may promote apoptosis and Wnt signaling. The suppression  
715 of cell death of immature neurons and adequate synaptic transmission at the axon terminals  
716 driven by insulin may be key factors in the recovery of the OE and rewiring in the OB.

717         Our observation of enhanced caspase activation in new neurons of STZ mice might  
718 reflect the decreased neuronal activity under reduced insulin. Neuronal activity, which is  
719 characterized by the generation of action potentials, leads to increased cytoplasmic cAMP levels  
720 (Fiske and Brunjes, 2001; Watt et al., 2004; Turrigiano, 2012; Francois et al., 2013) and  
721 subsequent phosphoinositide 3-kinase–AKT signaling (Balazs et al., 1988; Barger, 1999; Watt et  
722 al., 2004; Hyman and Yuan, 2012). These signals inhibit the intrinsic apoptosis machinery,  
723 thereby preventing cellular suicide (Raff, 1992; Burek and Oppenheim, 1996; Frade et al., 1996;  
724 Nunez and del Peso, 1998; Song and Poo, 1999; Vaux and Korsmeyer, 1999; Duarte et al.,

725 2012). Patch-clamp recordings in rats have shown that insulin regulates the spontaneous firing  
726 of action potentials in olfactory neurons (Savigner et al., 2009). Furthermore, neuronal activity  
727 induces synapse maturation by promoting the incorporation of NMDA receptors containing the  
728 subunit 2A and the recruitment of AMPA receptors to the postsynaptic site to activate silent  
729 synapses and to increase the strength of synaptic transmission (Isaac et al., 1995; Wu et al.,  
730 1996; Li and Sheng, 2003). Accordingly, the loss of insulin may result in reduced activity in  
731 OSNs and a failure to establish stabilized synaptic connections with target OB neurons, thereby  
732 ultimately contributing to the induction of apoptosis. Importantly, *Insr* is highly expressed in the  
733 OB (Fernandez and Torres-Aleman, 2012) and OSN apoptosis occurs around when OMP  
734 expression begins and when OSNs are born following OB ablation (Schwob et al., 1992;  
735 Coleman JH et al., 2019). Thus, insulin in the OB may also contribute to maturation of OSNs.

736

### 737 **Time-dependent insulin in newly generated OSNs**

738 We observed that insulin deficiency and blocking insulin receptors during days 8–13 after injury  
739 reduced the incorporation of new OSNs. During the period, both increased apoptotic cell death  
740 of immature OSNs and *Insr* upregulation were observed. Furthermore, nasal insulin application  
741 during the same period promoted the maturation of OSNs in control mice. These results indicate  
742 that the susceptibility of new OSNs to apoptosis varies according to their maturation stage and  
743 that new OSNs have a critical stage (8 – 13 days following injury) during which they are highly  
744 dependent on insulin for maturation. This stage corresponds to the growth of axons into the OB  
745 and subsequent expression of VGluT2, for the vesicular release of glutamate (Miragall and  
746 Monti Graziadei, 1982; Rodriguez-Gil et al., 2015; Liberia T et al., 2019). Insulin also regulates  
747 neurite outgrowth in cultured neurons and spine density (Govind et al., 2001; Choi et al., 2005),  
748 promotes the surface expression of recombinant NMDA receptors on *Xenopus* oocytes  
749 (Skeberdis et al., 2001), and accelerates the insertion of GluR1-containing AMPA receptors into  
750 the membranes of cultured hippocampal neurons (Passafaro et al., 2001). Conversely, an



751 attenuation of insulin signaling reduces AMPA mEPSC frequency and synaptic contacts onto  
752 tectal neurons (Chiu and Cline, 2010), leading to functionally incomplete synaptogenesis.  
753 Therefore, we speculate that insulin receptor-mediated signaling supports the growth of axons  
754 of newly generated OSNs to the target sites and the development of synapses, contributing to  
755 their incorporation into and maintenance within the olfactory neural circuits. Under conditions  
756 of low (or no) insulin receptor-mediated signaling, the axons of new neurons failed to reach  
757 postsynaptic sites and establish appropriate connections with OB neurons, resulting in the  
758 activation of apoptotic cascades that would otherwise be prevented with successful and  
759 functional integration into the circuit. Under conditions of sufficient insulin levels, the axons of  
760 new OSNs effectively reach the OB, resulting in the promotion of OSN maturation. The axon  
761 development and formation of functional synapses with OB neurons might be the  
762 insulin-dependent processes that explain the insulin-sensitive period in new neurons 8 – 13 days  
763 after the injury.

764           From a clinical perspective, olfactory damage, such as from traumatic injury, viral  
765 infections, and rhinosinusitis, diminishes an individual's quality of life. In some cases,  
766 functional recovery from damage is incomplete despite continuous OSN regeneration (Schwob,  
767 2002). Potential therapeutic options that help achieve complete tissue regrowth and functional  
768 recovery are not fully established. If insulin is important for the maturation and survival of new  
769 OSNs in the OE, intranasal administration represents a potential therapeutic option for olfactory  
770 dysfunction. The results from this study indicate that application between 8 - 13 days after  
771 injury would be the most effective to promote OE recovery. An improved understanding of the  
772 molecular and cellular mechanisms involved in the insulin-dependent period of OE regeneration  
773 should facilitate the effective utilization of insulin administration for the recovery of olfactory  
774 functions.

775 **References**

- 776 Aberg MA, Aberg ND, Hedbacker H, Oscarsson J, Eriksson PS (2000) Peripheral infusion of  
777 IGF-I selectively induces neurogenesis in the adult rat hippocampus. *J Neurosci*  
778 20:2896-2903.
- 779 Balazs R, Jorgensen OS, Hack N (1988) N-methyl-D-aspartate promotes the survival of  
780 cerebellar granule cells in culture. *Neuroscience* 27:437-451.
- 781 Banks WA (2004) The source of cerebral insulin. *Eur J Pharmacol* 490:5-12.
- 782 Barger SW (1999) Complex influence of the L-type calcium-channel agonist BayK8644(+/-) on  
783 N-methyl-D-aspartate responses and neuronal survival. *Neuroscience* 89:101-108.
- 784 Barrios AW, Nunez G, Sanchez Quinteiro P, Salazar I (2014) Anatomy, histochemistry, and  
785 immunohistochemistry of the olfactory subsystems in mice. *Front Neuroanat* 8:63.
- 786 Baura GD, Foster DM, Porte D, Jr., Kahn SE, Bergman RN, Cobelli C, Schwartz MW (1993)  
787 Saturable transport of insulin from plasma into the central nervous system of dogs in  
788 vivo. A mechanism for regulated insulin delivery to the brain. *J Clin Invest*  
789 92:1824-1830.
- 790 Benson TE, Ryugo DK, Hinds JW (1984) Effects of sensory deprivation on the developing  
791 mouse olfactory system: a light and electron microscopic, morphometric analysis. *J*  
792 *Neurosci* 4:638-653.
- 793 Blazquez E, Velazquez E, Hurtado-Carneiro V, Ruiz-Albusac JM (2014) Insulin in the brain: its  
794 pathophysiological implications for States related with central insulin resistance, type 2  
795 diabetes and Alzheimer's disease. *Front Endocrinol* 5:161.
- 796 Bozza T, Feinstein P, Zheng C, Mombaerts P (2002) Odorant receptor expression defines  
797 functional units in the mouse olfactory system. *J Neurosci* 22:3033-3043.
- 798 Brittebo EB (1995) Metabolism-dependent toxicity of methimazole in the olfactory nasal  
799 mucosa. *Pharmacol Toxicol* 76:76-79.
- 800 Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W,  
801 Muller-Wieland D, Kahn CR (2000) Role of brain insulin receptor in control of body  
802 weight and reproduction. *Science* 289:2122-2125.
- 803 Burek MJ, Oppenheim RW (1996) Programmed cell death in the developing nervous system.  
804 *Brain Pathol* 6:427-446.
- 805 Chiu SL, Cline HT (2010) Insulin receptor signaling in the development of neuronal structure  
806 and function. *Neural development* 5:7.
- 807 Choi J, Ko J, Racz B, Burette A, Lee JR, Kim S, Na M, Lee HW, Kim K, Weinberg RJ, Kim E  
808 (2005) Regulation of dendritic spine morphogenesis by insulin receptor substrate 53, a  
809 downstream effector of Rac1 and Cdc42 small GTPases. *J Neurosci* 25:869-879.
- 810 Duarte AI, Moreira PI, Oliveira CR (2012) Insulin in central nervous system: more than just a

- 811 peripheral hormone. *J Aging Res* 2012:384017.
- 812 Farbman AI, Brunjes PC, Rentfro L, Michas J, Ritz S (1988) The effect of unilateral naris  
813 occlusion on cell dynamics in the developing rat olfactory epithelium. *J Neurosci*  
814 8:3290-3295.
- 815 Fernandez AM, Torres-Aleman I (2012) The many faces of insulin-like peptide signalling in the  
816 brain. *Nat Rev Neurosci* 13:225-239.
- 817 Fiske BK, Brunjes PC (2001) Cell death in the developing and sensory-deprived rat olfactory  
818 bulb. *J Comp Neurol* 431:311-319.
- 819 Frade JM, Rodriguez-Tebar A, Barde YA (1996) Induction of cell death by endogenous nerve  
820 growth factor through its p75 receptor. *Nature* 383:166-168.
- 821 Francois A, Laziz I, Rimbaud S, Grebert D, Durieux D, Pajot-Augy E, Meunier N (2013) Early  
822 survival factor deprivation in the olfactory epithelium enhances activity-driven survival.  
823 *Front Cell Neurosci* 7:271.
- 824 Furman BL (2015) Streptozotocin-Induced Diabetic Models in Mice and Rats. *Curr Protoc*  
825 *Pharmacol* 70:5 47 41-20.
- 826 Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. *Circ Res*  
827 107:1058-1070.
- 828 Gogos JA, Osborne J, Nemes A, Mendelsohn M, Axel R (2000) Genetic ablation and  
829 restoration of the olfactory topographic map. *Cell* 103:609-620.
- 830 Goldberg JL, Barres BA (2000) The relationship between neuronal survival and regeneration.  
831 *Annu Rev Neurosci* 23:579-612.
- 832 Govind S, Kozma R, Monfries C, Lim L, Ahmed S (2001) Cdc42Hs facilitates cytoskeletal  
833 reorganization and neurite outgrowth by localizing the 58-kD insulin receptor substrate  
834 to filamentous actin. *J Cell Biol* 152:579-594.
- 835 Gray SM, Meijer RI, Barrett EJ (2014) Insulin regulates brain function, but how does it get  
836 there? *Diabetes* 63:3992-3997.
- 837 Hyman BT, Yuan J (2012) Apoptotic and non-apoptotic roles of caspases in neuronal  
838 physiology and pathophysiology. *Nat Rev Neurosci* 13:395-406.
- 839 Isaac JT, Nicoll RA, Malenka RC (1995) Evidence for silent synapses: implications for the  
840 expression of LTP. *Neuron* 15:427-434.
- 841 Ishikawa H, Ochi H, Chen ML, Frenkel D, Maron R, Weiner HL (2007) Inhibition of  
842 autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. *Diabetes*  
843 56:2103-2109.
- 844 Jing YH, Qi CC, Yuan L, Liu XW, Gao LP, Yin J (2017) Adult neural stem cell dysfunction in  
845 the subventricular zone of the lateral ventricle leads to diabetic olfactory defects. *Neural*  
846 *Regen Res* 12:1111-1118.

- 847 Kikuta S, Sakamoto T, Nagayama S, Kanaya K, Kinoshita M, Kondo K, Tsunoda K, Mori K,  
848 Yamasoba T (2015) Sensory deprivation disrupts homeostatic regeneration of newly  
849 generated olfactory sensory neurons after injury in adult mice. *J Neurosci*  
850 35:2657-2673.
- 851 Kuwabara T, Hsieh J, Muotri A, Yeo G, Warashina M, Lie DC, Moore L, Nakashima K,  
852 Asashima M, Gage FH (2009) Wnt-mediated activation of NeuroD1 and retro-elements  
853 during adult neurogenesis. *Nature Neurosci* 12:1097-1105.
- 854 Lacroix MC, Rodriguez-Enfedaque A, Grebert D, Laziz I, Meunier N, Monnerie R, Persuy MA,  
855 Riviere S, Caillol M, Renaud F (2011) Insulin but not leptin protects olfactory mucosa  
856 from apoptosis. *J Neuroendocrinol* 23:627-640.
- 857 Lacroix MC, Badonnel K, Meunier N, Tan F, Schlegel-Le Poupon C, Durieux D, Monnerie R,  
858 Baly C, Congar P, Salesse R, Caillol M (2008) Expression of insulin system in the  
859 olfactory epithelium: first approaches to its role and regulation. *J Neuroendocrinol*  
860 20:1176-1190.
- 861 Laron Z (2009) Insulin and the brain. *Arch Physiol Biochem* 115:112-116.
- 862 Li Z, Sheng M (2003) Some assembly required: the development of neuronal synapses. *Nature*  
863 *Rev Mol Cell Biol* 4:833-841.
- 864 Liberia T, Martin-Lopez E, Meller SJ, Greer CA (2019) Sequential Maturation of Olfactory  
865 Sensory Neurons in the Mature Olfactory Epithelium. *eNeuro*  
866 16;6(5):ENEURO.0266-19.2019.
- 867 Magklara A, Lomvardas S (2013) Stochastic gene expression in mammals: lessons from  
868 olfaction. *Trends Cell Biol.* 23:449-456.
- 869 Marks DR, Tucker K, Cavallin MA, Mast TG, Fadool DA (2009) Awake intranasal insulin  
870 delivery modifies protein complexes and alters memory, anxiety, and olfactory  
871 behaviors. *J Neurosci* 29:6734-6751.
- 872 McEntire JK, Pixley SK (2000) Olfactory receptor neurons in partially purified epithelial cell  
873 cultures: comparison of techniques for partial purification and identification of insulin  
874 as an important survival factor. *Chem senses* 25:93-101.
- 875 Mielke JG, Taghibiglou C, Wang YT (2006) Endogenous insulin signaling protects cultured  
876 neurons from oxygen-glucose deprivation-induced cell death. *Neuroscience*  
877 143:165-173.
- 878 Miragall F, Monti Graziadei GA (1982) Experimental studies on the olfactory marker protein. II.  
879 Appearance of the olfactory marker protein during differentiation of the olfactory  
880 sensory neurons of mouse: an immunohistochemical and autoradiographic study. *Brain*  
881 *Res* 239:245-250.
- 882 Mori K, Sakano H (2011) How is the olfactory map formed and interpreted in the mammalian

- 883 brain? *Annu Rev Neurosci* 34:467-499.
- 884 Nunez G, del Peso L (1998) Linking extracellular survival signals and the apoptotic machinery.
- 885 *Curr Opin Neurobiol* 8:613-618. doi: 10.1016/s0959-4388(98)80089-5, PMID:
- 886 9811624.
- 887 Ohmoto M, Matsumoto I, Yasuoka A, Yoshihara Y, Abe K (2008) Genetic tracing of the
- 888 gustatory and trigeminal neural pathways originating from T1R3-expressing taste
- 889 receptor cells and solitary chemoreceptor cells. *Mol Cell Neurosci* 38:505-517.
- 890 Oka Y, Katada S, Omura M, Suwa M, Yoshihara Y, Touhara K (2006) Odorant receptor map in
- 891 the mouse olfactory bulb: in vivo sensitivity and specificity of receptor-defined
- 892 glomeruli. *Neuron* 52:857-869.
- 893 Pacold ST, Blackard WG (1979) Central nervous system insulin receptors in normal and
- 894 diabetic rats. *Endocrinology* 105:1452-1457.
- 895 Palouzier-Paulignan B, Lacroix MC, Aimé P, Baly C, Caillol M, Congar P, Julliard AK, Tucker
- 896 K, Fadool DA (2012) Olfaction under metabolic influences. *Chem Senses* 37:769-797.
- 897 Passafaro M, Piech V, Sheng M (2001) Subunit-specific temporal and spatial patterns of AMPA
- 898 receptor exocytosis in hippocampal neurons. *Nature Neurosci* 4:917-926.
- 899 Pezzino V, Costantino A, Russo P, Gullo D, Papa V (1996) Insulin receptor content in tissues of
- 900 normal and diabetic rats measured by radioimmunoassay. *J Endocrinol Invest*
- 901 19:593-597.
- 902 Pietra G, Dibattista M, Menini A, Reisert J, Boccaccio A (2016) The Ca<sup>2+</sup>-activated Cl<sup>-</sup>
- 903 channel TMEM16B regulates action potential firing and axonal targeting in olfactory
- 904 sensory neurons. *J Gen Physiol* 148:293-311.
- 905 Plum L, Schubert M, Bruning JC (2005) The role of insulin receptor signaling in the brain.
- 906 *Trends Endocrinol Metab* 16:59-65.
- 907 Raff MC (1992) Social controls on cell survival and cell death. *Nature* 356:397-400.
- 908 Rodriguez-Gil DJ, Bartel DL, Jaspers AW, Mobley AS, Imamura F, Greer CA (2015) Odorant
- 909 receptors regulate the final glomerular coalescence of olfactory sensory neuron axons.
- 910 *Proc Natl Acad Sci U S A*. 112:5821-5826.
- 911 Sakamoto T, Kondo K, Kashio A, Suzukawa K, Yamasoba T (2007) Methimazole-induced cell
- 912 death in rat olfactory receptor neurons occurs via apoptosis triggered through
- 913 mitochondrial cytochrome c-mediated caspase-3 activation pathway. *J Neurosci Res*
- 914 85:548-557.
- 915 Saraiva LR, Ibarra-Soria X, Khan M, Omura M, Scialdone A, Mombaerts P, Marioni JC, Logan
- 916 DW (2015) Hierarchical deconstruction of mouse olfactory sensory neurons: from
- 917 whole mucosa to single-cell RNA-seq. *Sci Rep* 5:18178.
- 918 Savigner A, Duchamp-Viret P, Grosmaître X, Chaput M, Garcia S, Ma M, Palouzier-Paulignan

- 919 B (2009) Modulation of spontaneous and odorant-evoked activity of rat olfactory  
920 sensory neurons by two anorectic peptides, insulin and leptin. *J Neurophysiol*  
921 101:2898-2906.
- 922 Schwob JE, Szumowski KE, Stasky AA (1992) Olfactory sensory neurons are trophically  
923 dependent on the olfactory bulb for their prolonged survival. *J Neurosci* 12:3896-3919.
- 924 Schwob JE (2002) Neural regeneration and the peripheral olfactory system. *Anat Rec*  
925 269:33-49.
- 926 Coleman JH, Lin B, Louie JD, Peterson J, Lane RP, Schwob JE (2019) Spatial Determination of  
927 Neuronal Diversification in the Olfactory Epithelium. *J Neurosci* 39:814-832.
- 928 Sechi LA, Griffin CA, Grady EF, Grunfeld C, Kalinyak JE, Schambelan M (1992)  
929 Tissue-specific regulation of insulin receptor mRNA levels in rats with STZ-induced  
930 diabetes mellitus. *Diabetes* 41:1113-1118.
- 931 Skeberdis VA, Lan J, Zheng X, Zukin RS, Bennett MV (2001) Insulin promotes rapid delivery  
932 of N-methyl-D- aspartate receptors to the cell surface by exocytosis. *Proc Natl Acad Sci*  
933 U S A. 98:3561-3566.
- 934 Song HJ, Poo MM (1999) Signal transduction underlying growth cone guidance by diffusible  
935 factors. *Curr Opin Neurobiol* 9:355-363.
- 936 Stephan AB, Tobochnik S, Dibattista M, Wall CM, Reisert J, Zhao H (2011) The Na<sup>(+)</sup>/Ca<sup>(2+)</sup>  
937 exchanger NCKX4 governs termination and adaptation of the mammalian olfactory  
938 response. *Nat Neurosci* 15:131-137.
- 939 Turrigiano G (2012) Homeostatic synaptic plasticity: local and global mechanisms for  
940 stabilizing neuronal function. *Cold Spring Harb Perspect Biol* 4:a005736.
- 941 Valenciano AI, Corrochano S, de Pablo F, de la Villa P, de la Rosa EJ (2006) Proinsulin/insulin  
942 is synthesized locally and prevents caspase- and cathepsin-mediated cell death in the  
943 embryonic mouse retina. *J Neurochem* 99:524-536.
- 944 Vaux DL, Korsmeyer SJ (1999) Cell death in development. *Cell* 96:245-254.
- 945 Wan Q, Xiong ZG, Man HY, Ackerley CA, Braunton J, Lu WY, Becker LE, MacDonald JF,  
946 Wang YT (1997) Recruitment of functional GABA(A) receptors to postsynaptic  
947 domains by insulin. *Nature* 388:686-690.
- 948 Watt WC, Sakano H, Lee ZY, Reusch JE, Trinh K, Storm DR (2004) Odorant stimulation  
949 enhances survival of olfactory sensory neurons via MAPK and CREB. *Neuron*  
950 41:955-967.
- 951 Wu G, Malinow R, Cline HT (1996) Maturation of a central glutamatergic synapse. *Science*  
952 274:972-976.
- 953 Yamaguchi T, Yamashita J, Ohmoto M, Aoudé I, Ogura T, Luo W, Bachmanov AA, Lin W,  
954 Matsumoto I, Hirota J (2014) *Skn-1a/Pou2f3* is required for the generation of

955 Trpm5-expressing microvillous cells in the mouse main olfactory epithelium. BMC  
956 Neurosci 16;15:13.  
957

958 **Figure Legends**

959 **Figure 1.** Decreased insulin for 90 days does not induce histological changes in OE.

960 **A, B,** *Insr* mRNA of uninjured OEs detected by *in situ* hybridization using digoxigenin-labeled  
961 antisense RNA and RNAscope probes. Representative image for an *in situ* hybridization using  
962 digoxigenin-labeled antisense RNA of *Insr* of an uninjured OE in a 3-wk-old mouse ( $n = 2$  mice)  
963 (**A**) and image for an RNAscope assay against *Insr* shown as small brown dots on an uninjured  
964 OE of a 10-wk-old mouse ( $n = 2$  mice) (**B**). Signals were detected especially in the apical and  
965 bottom layers of the OE, where supporting cells and immature OSNs, respectively, are located  
966 (middle panel in **A**). Arrowheads indicate the non-homogeneous staining with higher level of *Insr*  
967 expression (**A, B**). Scale bars: 250  $\mu\text{m}$  at low magnification, 50  $\mu\text{m}$  at higher magnification.

968 **C,** Protocol of STZ treatment. STZ was intraperitoneally (i.p.) injected on days 0, 1, and 2. Mice  
969 with a fasting blood glucose (FBS)  $\geq 250$  mg/dl were considered diabetic.

970 **D,** Fasted and fed blood glucose levels before and after STZ administration. Both fasted and fed  
971 blood glucose levels after STZ administration (post-STZ) were much higher than those before  
972 STZ administration (pre-STZ) (Steel-Dwass test).

973 **E,** Body weights before and after STZ administration. There was no significant difference (n.s.)  
974 in body weights between pre-STZ and post-STZ (Mann-Whitney *U* test).

975 **F,** Experiment timelines for STZ mice obtained at 28 and 90 days, and saline-injected (i.p.)  
976 control mice for comparison at 28 days.

977 **G, H,** Representative coronal sections of nasal septa showing the OEs stained with hematoxylin  
978 and anti-OMP antibody (green) from STZ mice on day 28 (**G**) or day 90 (**H**) after saline  
979 injection. Left images, lower magnification; right upper (hematoxylin) and lower (OMP)  
980 images, higher magnifications of the OE depicted in the left photographs indicated by squares.  
981 Scale bars: 100  $\mu\text{m}$  at lower magnification, 50  $\mu\text{m}$  at higher magnification.

982 **I, J,** Thicknesses of the OEs (**I**) and density of OSNs (**J**) in STZ-d28, STZ-d90, and saline-d28  
983 mice. There were no significant differences between STZ-d28 and STZ-d90 or STZ-d90 and



984 saline-d28 mice (thickness: two-way RM ANOVA, Day:  $F(1, 15) = 0.17, p = 0.682$ , Treatment:  
985  $F(1, 15) = 4.21, p = 0.058$ ; Interaction:  $F(1, 15), p = 0.800$ ; number of OSNs: two-way RM  
986 ANOVA, Day:  $F(1, 15), p = 0.725$ ; Treatment:  $F(1, 15), p = 0.913$ ; Interaction:  $F(1, 15), p =$   
987  $0.595$ ). Data points represent the value in the analyzed areas of OE (8 areas / mouse; saline-d28 ( $n$   
988  $= 3$  mice), STZ-d28 ( $n = 3$  mice), saline-d90 ( $n = 3$ ), STZ-d90 ( $n = 2$  mice).

989 **K**, Odorant-evoked EOG responses to pentyl acetate at different concentrations in control and  
990 STZ mice on day 90 without injury. Similar response kinetics of the EOG were observed in  
991 control and STZ mice.

992 **L**, Comparison of peak amplitudes in EOG recordings between control and STZ mice ( $n = 6$   
993 mice/group) on day 90 without injury. Relative to control mice, the EOG amplitudes in response  
994 to each of all concentrations of pentyl acetate were not significantly different in STZ mice  
995 (two-way RM ANOVA, Odor concentration:  $F(1, 5) = 181.32, p < 0.001$ ; STZ treatment:  $F(1,$   
996  $5) = 1.16, p = 0.330$ ; Interaction:  $F(1, 5) = 0.950, p = 0.374$ ). Error bars, SD.

997

998 **Figure 2.** Decreased insulin disrupts OE recovery following methimazole-induced injury.

999 **A**, Time course of the experimental design in both control and STZ mice. Methimazole was  
1000 injected (i.p.), and the tissues were fixed (“fix.”) after 3, 7, 14, and 28 days.

1001 **B**, Representative coronal sections of the nasal septa stained with hematoxylin 3, 7, 14, and 28  
1002 days after methimazole-induced injury in both control and STZ mice. Scale bars, 50  $\mu\text{m}$ .

1003 **C, D**, The OE thicknesses (**C**) (two-way RM ANOVA with Bonferroni’s post-hoc correction,  
1004 Day:  $F(2, 44) = 79.92, p < 0.001$ ; Treatment:  $F(1, 22) = 28.51, p < 0.001$ ; Interaction:  $F(2, 44)$   
1005  $= 5.16, p = 0.014$ ) and the density of OSNs (**D**) (two-way RM ANOVA with Bonferroni’s  
1006 post-hoc correction, Day:  $F(1, 22) = 131.27, p < 0.001$ ; Treatment:  $F(1, 22) = 40.89, p < 0.001$ ;  
1007 Interaction:  $F(1, 22) = 4.38, p = 0.048$ ) for control, STZ, and saline-administered mice on days  
1008 7 (d7), 14 (d14), and 28 (d28) after methimazole-induced injury. On days 14 and 28, the OE  
1009 thickness and density of OSNs in STZ mice were reduced significantly compared to those in

1010 control mice (\*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ ; Bonferroni's post-hoc test). On day 28 following  
1011 methimazole-induced injury, the thickness of the OEs and the density of OSNs in the control  
1012 mice were restored to levels similar to those in saline-administered mice (n.s., not significant;  
1013 Mann-Whitney  $U$  test). Data points represent the value in the analyzed areas of OE [8 areas /  
1014 mouse; control ( $n = 3$  mice / timepoint), STZ ( $n = 3$  mice / timepoint)].

1015 **E**, Representative coronal sections stained with anti-OMP antibody (green) 7, 14, and 28 days  
1016 after methimazole-induced injury in control and STZ mice. Scale bar, 50  $\mu\text{m}$ .

1017 **F**, Density of OMP-positive cells in control and STZ mice. Two-way RM ANOVA with  
1018 Bonferroni's post-hoc correction, Day:  $F(1, 23) = 113.60$ ,  $p < 0.001$ ; Treatment:  $F(1, 23) =$   
1019  $216.69$ ,  $p < 0.001$ ; Interaction:  $F(1, 23) = 0.95$ ,  $p = 0.338$ . On days 14 and 28 following  
1020 methimazole-induced injury, the density of OMP-positive cells was significantly lower in STZ  
1021 mice than in control mice (\*\*\*  $p < 0.001$ ; Bonferroni's post-hoc test). The density of  
1022 OMP-positive cells in control mice 28 days after injury was restored to levels observed in  
1023 saline-administered mice (n.s., not significant; Mann-Whitney  $U$  test). Data points represent the  
1024 value in the analyzed areas of OE [8 areas / mouse; control ( $n = 3$  mice / timepoint), STZ ( $n = 3$   
1025 mice / timepoint), saline-d28 ( $n = 2$  mice)].

1026

1027 **Figure 3.** OSNs in STZ mice display reduced odorant-evoked responses.

1028 **A**, Odorant-evoked EOG responses to pentyl acetate at different concentrations in control and  
1029 STZ mice on day 14 following injury. Similar response kinetics of the EOG were observed in  
1030 control and STZ mice.

1031 **B**, Comparison of peak amplitudes in EOG recordings between control and STZ mice on day 14  
1032 following injury. Two-way RM ANOVA with Bonferroni's post-hoc correction, Odor  
1033 concentration:  $F(1, 5) = 89.65$ ,  $p < 0.001$ ; STZ treatment:  $F(1, 5) = 13.51$ ,  $p = 0.014$ ;  
1034 Interaction:  $F(1, 5) = 12.84$ ,  $p = 0.016$ . Relative to control mice, STZ mice showed significantly  
1035 lower EOG amplitudes in response to high concentrations of pentyl acetate ( $10^{-1}$  M,  $p < 0.001$ ;

1036  $10^{-2}$  M,  $p < 0.001$ ; \*\*\*  $p < 0.001$ ;  $n = 6$  mice / group; Bonferroni's post-hoc test). Error bars,  
1037 SD.

1038 **C**, Odorant-evoked EOG responses to pentyl acetate at different concentrations in control and  
1039 STZ mice on day 28 following injury. Similar response kinetics of the EOG were observed in  
1040 control and STZ mice.

1041 **D**, Comparison of peak amplitudes in EOG recordings between control and STZ mice on day 28  
1042 following injury. Two-way RM ANOVA with Bonferroni's post-hoc correction, Odor  
1043 concentration:  $F(1, 5) = 83.27$ ,  $p < 0.001$ ; STZ treatment:  $F(1, 5) = 14.14$ ,  $p = 0.013$ ;  
1044 Interaction:  $F(1, 5) = 9.94$ ,  $p = 0.025$ . Relative to control mice, STZ mice showed significantly  
1045 lower EOG amplitudes in response to high concentrations of pentyl acetate ( $10^{-1}$  M,  $p < 0.001$ ;  
1046  $10^{-2}$  M,  $p < 0.001$ ;  $10^{-3}$  M,  $p = 0.047$ ; \*  $p < 0.05$ , \*\*\*  $p < 0.001$ ;  $n = 6$  mice/group; Bonferroni's  
1047 post-hoc test). Error bars, SD.

1048

1049 **Figure 4.** Decreased insulin impairs axonal targeting to glomeruli in the OB.

1050 **A**, Representative coronal sections stained with anti-OMP antibody 14 and 28 days after  
1051 methimazole-induced injury in control and STZ mice. Each circled area corresponds to a  
1052 glomerulus. Scale bar, 100  $\mu$ m.

1053 **B**, Percentages of OMP-stained areas in the medial glomeruli of the OB. The percentages were  
1054 significantly reduced in STZ mice 14 and 28 days after methimazole-induced injury [d14:  $n =$   
1055 123 glomeruli in 3 mice (control),  $n = 190$  glomeruli in 4 mice (STZ); d28:  $n = 207$  glomeruli in  
1056 5 mice (control),  $n = 118$  glomeruli in 4 mice (STZ); \*\*\*  $p < 0.001$ , Friedman test followed by  
1057 Mann-Whitney  $U$  test with Bonferroni correction].

1058 **C**, Time course and experiment design used to test control and STZ mOR-EG-GFP mice.  
1059 Methimazole was injected i.p., and the tissue was fixed 45 days later.

1060 **D**, Representative sections of GFP-expressing glomeruli in control and STZ mOR-EG-GFP  
1061 mice 45 days after injury. Axonal targeting was disturbed with different patterns in STZ

1062 mOR-EG-GFP mice (#1 and 2 in lower panel). Dashed circles, glomeruli. Scale bar, 100  $\mu$ m.

1063 **E**, Percentages of GFP-positive areas within glomeruli. The GFP-labeled area was significantly  
1064 reduced in STZ-administered mOR-EG-GFP mice [ $n = 81$  glomeruli in 6 mice (control),  $n = 39$   
1065 glomeruli in 4 mice (STZ), \*\*\*  $p < 0.001$ , Mann-Whitney  $U$  test].

1066 **F**, Sizes of glomeruli. The mean glomerular sizes were not significantly different between  
1067 control and STZ mOR-EG-GFP mice [ $n = 81$  glomeruli in 6 mice (control),  $n = 39$  glomeruli in  
1068 4 mice (STZ), n.s., not significant, Mann-Whitney  $U$  test].

1069 **G**, Timeline for odorant-induced c-Fos expression experiment. The fixation and the  
1070 immunostaining were performed for control and STZ mice 28 days after methimazole-induced  
1071 injury. Odorants in three categories (aldehydes, lactones, and esters) were applied by placing the  
1072 odor-containing dish in a cage twice for 1 h with a 10-min interval between placements (right).

1073 **H**, Representative coronal sections of the OB stained with anti-c-Fos antibody. Left, schematic  
1074 of a coronal OB displaying four quadrants. Right, c-Fos expression of the d-m areas in control  
1075 and STZ mice. Scale bar, 100  $\mu$ m.

1076 **I**, Density of c-Fos-positive cells in the glomerular layers in each quadrant of the OB. The  
1077 densities were significantly smaller in STZ mice than in control mice 28 days after  
1078 methimazole-induced injury (\*\*  $p < 0.01$ ; Mann-Whitney  $U$  test). Data points represent the  
1079 value in the analyzed areas of OB [2-3 areas / region / mouse;  $n = 4$  mice (control),  $n = 5$  mice  
1080 (STZ)].

1081

1082 **Figure 5.** Decreased insulin elicits behavioral deficits in STZ mice 28 days after  
1083 methimazole-induced injury.

1084 **A**, Time course of the experimental design for the odor-guided food-seeking test.

1085 **B**, Diagram displaying the experimental design of the buried food test. On trial days 1–3, a  
1086 piece of cookie was buried under the bedding in a randomly selected corner of the mouse cage.  
1087 On trial day 4, a piece of cookie was placed on top of the bedding to be visible to the mice.

1088 **C**, Latencies to find the cookie on each trial day in control and STZ mice 28 days after  
1089 methimazole-induced injury. Two-way RM ANOVA with Tukey post-hoc test, Day,  $F(1, 6) =$   
1090  $23.26, p < 0.001$ , STZ treatment,  $F(1, 6) = 28.82, p = 0.002$ , Interaction,  $F(1, 6) = 2.93, p <$   
1091  $0.138$ . The latency in STZ mice was significantly longer than that in control mice on trial day 1,  
1092 2, and 3 ( $n = 7$  mice / group; error bars, SD; \*\*  $p < 0.01$ , n.s., not significant; Tukey post-hoc  
1093 test).

1094

1095 **Figure 6.** Decreased insulin does not alter OSN proliferation but increases apoptotic cell death  
1096 in immature neurons.

1097 **A**, Representative coronal sections of nasal septa stained with anti-Ki67 antibody for control  
1098 and STZ mice 3, 7, 14, and 28 days after methimazole-induced injury. Arrowheads indicate  
1099 Ki67-positive cells. Scale bar, 50  $\mu\text{m}$ .

1100 **B**, Density of Ki67-positive cells in the nasal septa of control and STZ mice 3, 7, 14, and 28  
1101 days after methimazole-induced injury. Two-way RM ANOVA with Bonferroni's post-hoc  
1102 correction, Day:  $F(1, 15) = 33.87, p < 0.001$ ; STZ treatment:  $F(1, 15) = 14.25, p = 0.002$ ;  
1103 Interaction:  $F(1, 15) = 0.15, p = 0.858$ . No significant differences in the numbers of  
1104 Ki67-positive cells were observed between control and STZ mice [d3:  $p = 1.000$ , 3 mice  
1105 (control) vs. 3 mice (STZ); d7:  $p = 1.000$ , 2 mice (control) vs. 3 mice (STZ); d14:  $p = 1.000$ , 3  
1106 mice (control) vs. 3 mice (STZ); d28:  $p = 1.000$ , 3 mice (control) vs. 3 mice (STZ); n.s., not  
1107 significant; Bonferroni's post-hoc test]. Data points represent the value in the analyzed areas of  
1108 OE (8 areas / mouse).

1109 **C**, Representative coronal sections of nasal septa stained with anti-activated caspase-3 antibody  
1110 for control and STZ mice 7, 14, and 28 days after methimazole-induced injury. Arrowheads  
1111 indicate activated caspase-3-positive cells. Scale bars, 50  $\mu\text{m}$ .

1112 **D**, Density of activated caspase-3-positive cells in the nasal septa of control and STZ mice 7,  
1113 14, and 28 days after methimazole-induced injury. Two-way RM ANOVA with Bonferroni's

1114 post-hoc correction, Day:  $F(2, 34) = 154.62, p < 0.001$ ; STZ treatment:  $F(1, 17) = 316.92, p <$   
1115  $0.001$ ; Interaction:  $F(1, 17) = 148.56, p < 0.001$ . The susceptibility to apoptosis of new OSNs in  
1116 STZ mice was greatest on day 14 ( $n = 3$  mice;  $*** p < 0.001$ ; Bonferroni's post-hoc test). On  
1117 days 14 and 28, the total numbers of caspase-3-positive cells in STZ mice were significantly  
1118 higher than those in control mice ( $n = 3$  mice;  $*** p < 0.001$ ; Bonferroni's post-hoc test). Data  
1119 points represent the value in the analyzed areas of OE (8 areas / mouse).

1120 **E**, Representative coronal sections of nasal septa stained with anti-activated caspase-3 (red) and  
1121 anti-OMP (green) or anti-GAP43 (green) antibodies 14 days after methimazole-induced injury  
1122 in STZ mice. The majority of activated caspase-3-positive cells (white arrowheads) were  
1123 contained not by the anti-OMP but by the anti-GAP43 antibody. Scale bar, 20  $\mu\text{m}$ .

1124

1125 **Figure 7.** Newly generated OSNs require insulin during their maturation after day 7 post injury.

1126 **A**, Time course of the experimental design. Mice in three experimental groups were  
1127 administered insulin i.p. at different times following methimazole-induced injury.

1128 **B**, Representative coronal sections of the nasal septa stained with hematoxylin (upper) or  
1129 anti-OMP antibody (lower) for mice administered insulin on d1–13, d1–6, or d8–13. Scale bars,  
1130 50  $\mu\text{m}$ .

1131 **C–E**, OE thicknesses (**C**) (Kruskal-Wallis test followed by Mann-Whitney  $U$  test with  
1132 Bonferroni correction,  $\chi^2 = 29.62, p < 0.001$ ), density of OSNs (**D**) (Kruskal-Wallis test followed  
1133 by Mann-Whitney  $U$  test with Bonferroni correction,  $\chi^2 = 28.02, p < 0.001$ ), and density of  
1134 OMP-positive cells (**E**) (Kruskal-Wallis test followed by Mann-Whitney  $U$  test with Bonferroni  
1135 correction,  $\chi^2 = 22.52, p < 0.001$ ) in the three groups [OE thickness: 3 mice (d1–13), 3 mice  
1136 (d1–6), 3 mice (d8–13); number of OSNs: 3 mice (d1–13), 3 mice (d1–6), 3 mice (d8–13);  
1137 number of OMPs: 4 mice (d1–13), 3 mice (d1–6), 3 mice (d8–13);  $*** p < 0.001$  for d1–13 vs.  
1138 d1–6 and for d1–6 vs. d8–13; Mann-Whitney  $U$  test with Bonferroni correction]. Data points  
1139 represent the value in the analyzed areas of OE (thickness: 5–6 areas / mouse; OSNs: 5–6 areas /

1140 mouse; OMPs: 4 areas / mouse).

1141 **F**, Diagram of intranasal insulin administration. Insulin was applied to the nasal cavities of STZ  
1142 mice after methimazole-induced injury. These applications were performed according to the  
1143 protocol used for the i.p. insulin administration shown in **A**.

1144 **G**, Effects of the intranasal insulin application on blood glucose levels. Shown are blood glucose  
1145 levels before (pre-ad) and 60 and 120 min after intranasal administration (after ad) of insulin at  
1146 three concentrations (\*  $p < 0.05$ ; \*\*  $p < 0.01$ ; Steel test).

1147 **H**, Representative coronal sections of nasal septa stained with anti-OMP antibody (green) 14  
1148 days after methimazole-induced injury in STZ mice. Scale bar, 50  $\mu\text{m}$ .

1149 **I**, Density of OMP-positive cells 14 days after methimazole-induced injury in the three  
1150 intranasal insulin administration groups. Kruskal-Wallis test followed by Mann-Whitney U test  
1151 with Bonferroni correction,  $\chi^2 = 37.47$ ,  $p < 0.001$ . ( $n = 3$  mice / group; \*\*\*  $p < 0.001$  for d1–13  
1152 vs. d1–6 and for d1–6 vs. d8–13; Mann-Whitney U test with Bonferroni correction). Data points  
1153 represent the value in the analyzed areas of OE (6 areas / mouse).

1154

1155 **Figure 8.** Upregulation of insulin receptor-mediated during day 8–13 is required for maturation  
1156 of OSNs.

1157 **A**, **B**, *In situ* hybridization by RNAscope assay of *Insr* from septal and turbinate coronal  
1158 sections of the uninjured OE and the OE on day 14 following injury (**A**) and medial part of  
1159 sections of the uninjured OB and the OB on day 14 following injury (**B**) in non-diabetic  
1160 10-wk-old mice. Signals were sparsely detected especially in the layer of supporting cells and  
1161 OSNs of the uninjured OE ( $n = 3$  mice) (left panels in **A**). Strong signals, suggesting  
1162 upregulation of *Insr* expression were detected in the OE on day 14 following injury ( $n = 3$  mice)  
1163 (right panels in **A**). In the OB, signals were detected in the glomerular layer (GL), external  
1164 plexiform layer (EPL), and mitral cell layer (MCL) (**B**). Signal intensity appears similar  
1165 between the uninjured OB ( $n = 3$  mice) (left panels in **B**) and the OB at day 14 following injury

1166 ( $n = 3$  mice) (right panels in **B**). Scale bars, 50  $\mu\text{m}$ .

1167 **C**, Time course of the experimental design. Mice in two experimental groups were administered  
1168 PBS or S961, an insulin receptor antagonist during day 8–13 following methimazole-induced  
1169 injury.

1170 **D**, Diagram of unilateral intranasal application. PBS or S961 was applied to a side of the nasal  
1171 cavities of non-diabetic control mice after methimazole-induced injury according to the protocol  
1172 shown in **C**.

1173 **E**, Effects of the intranasal S961 application (0.5  $\mu\text{g}/\mu\text{l}$ , 10  $\mu\text{l}$ ) on blood glucose levels before  
1174 (pre-S961) and 120 min after intranasal administration (after S961) of insulin.

1175 **F**, Representative coronal sections of the nasal septa stained with DAPI and anti-OMP antibody  
1176 (red) for control mice intranasally administered PBS or S961 on d8–13. Scale bars, 50  $\mu\text{m}$ .

1177 **G–I**, OE thicknesses (**G**) (Kruskal-Wallis test followed by Mann-Whitney  $U$  test with  
1178 Bonferroni correction,  $\chi^2 = 16.67$ ,  $p < 0.001$ ), density of OSNs (**H**) (Kruskal-Wallis test followed  
1179 by Mann-Whitney  $U$  test with Bonferroni correction,  $\chi^2 = 17.63$ ,  $p < 0.001$ ), and density of  
1180 OMP-positive cells (**I**) (Kruskal-Wallis test followed by Mann-Whitney  $U$  test with Bonferroni  
1181 correction,  $\chi^2 = 22.48$ ,  $p < 0.001$ ) in the three groups [OE thickness: 3 mice (PBS), 3 mice  
1182 (S961); number of OSNs: 3 mice (PBS), 3 mice (S961); number of OMPs: 3 mice (PBS), 3  
1183 mice (S961); \*  $p < 0.05$ , \*\*  $p < 0.01$ ; Mann-Whitney  $U$  test with Bonferroni correction]. PBS-C,  
1184 PBS-Control; S961-C, S961-Control. Data points represent the value in the analyzed areas of  
1185 OE (3 areas / side / mouse).

1186

1187 **Figure 9. Insulin enhances the replacement of newly generated OSNs in control mice.**

1188 **A**, Time course of the experimental design following methimazole and insulin application. Mice  
1189 in two experimental groups received unilateral intranasal insulin application at different periods  
1190 after methimazole-induced injury. Both groups received methimazole intraperitoneally (i.p.) on  
1191 day 0 and intranasal insulin starting on day 1. Mice were perfused with fixative on day 7 (d1-6



1192 insulin, left) or day 14 (d1-13 insulin, right) after the methimazole-induced injury.

1193 **B**, Representative images of the nasal septum stained with anti-olfactory marker protein (OMP)  
1194 (green) antibody in the two groups. Scale bar, 50  $\mu$ m.

1195 **C**, Number of olfactory marker protein (OMP)-positive cells in mice subjected to insulin  
1196 administration 1–13 days after the injury. The number of OMP-positive cells were significantly  
1197 increased on the insulin application side compared with the contralateral side ( $n = 4$  mice /  
1198 group; \*\*\* $p < 0.001$ ; Mann–Whitney test). Data points represent the value in the analyzed areas  
1199 of OE (6 areas / mouse).

1200 **D**, Time course of the experimental design of methimazole and insulin application. Mice in two  
1201 experimental groups received unilateral insulin application at different times after  
1202 methimazole-induced injury. Both groups received methimazole intraperitoneally on day 0.  
1203 Insulin was unilaterally applied on days 1–6 (left, d1-6 insulin) and days 8–13 (right, d8-13  
1204 insulin) post-injury three times daily. Mice were perfused with fixative on day 14 after the  
1205 methimazole-induced injury.

1206 **E**, Representative images of the olfactory nasal septum and concha bullosa stained with  
1207 anti-olfactory marker protein (OMP) (green) antibody in the two groups. App, application side;  
1208 contra, contralateral side. Scale bars, 50  $\mu$ m.

1209 **F**, Number of olfactory marker protein (OMP)-positive cells in mice subjected to insulin  
1210 application 1–6 days and 8–13 days after injury. Two-way RM ANOVA with Bonferroni’s  
1211 post-hoc correction, Day:  $F(1, 23) = 10.87$ ,  $p = 0.003$ ; application side:  $F(1, 23) = 4.60$ ,  $p =$   
1212  $0.043$ ; Interaction:  $F(1, 23) = 13.67$ ,  $p = 0.001$ . The number of OMP-positive cells on the  
1213 application side was significantly higher during the insulin application 8-13 days post-injury  
1214 than that on the contralateral side ( $n = 4$  mice / group; \*\*  $p < 0.01$ ; Bonferroni’s post-hoc test),  
1215 whereas no significant difference was observed between the application and contralateral sides  
1216 1-6 days post-injury (n.s., not significant; Bonferroni’s post-hoc test). Data points represent the  
1217 value in the analyzed areas of OE (6 areas / mouse).

1218

1219 **Figure 10.** Diagram for insulin-dependent replacement of newly generated OSNs following  
1220 injury.

1221 **A,** Time course of tissue structure in uninjured OE. Even under insulin-deficient situations, no  
1222 structural changes in the uninjured OE occur during the 90-day period.

1223 **B,** Time course of the repair process following injury. The dependence of the newly generated  
1224 OSNs on insulin increased between 8 and 13 days following injury. Under normal insulin levels,  
1225 newly generated OSNs regenerate and mature during days 8-13 following injury. The number of  
1226 mature OSNs gradually increases, and tissue repair is completed 28 days following injury.  
1227 However, under insulin-deficient situations during days 8-13 following injury, newly generated  
1228 OSNs are highly susceptible to apoptosis, resulting in incomplete recovery of the OE with fewer  
1229 mature OSNs. Under insulin-enriched situations during the same period, facilitation of the OE  
1230 repair could occur.

1231

1232 **Table 1.** Summary of mouse age at each experimental timepoint

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6






Figure 7




Figure 8




Figure 9






Figure 10

A Uninjured olfactory epithelium



B Injured olfactory epithelium



**Table 1. Summary of mouse age at each experimental timepoint**

<b>Experiments</b>	<b>Age of mouse when data was obtained</b>	<b>Streptozotocin i.p.</b>	<b>Methimazole i.p.</b>	<b>Number of mice (N)</b>
Figure 1A	3 weeks	N/A	N/A	N = 2
Figure 1B	10 weeks	N/A	N/A	N = 2
Figure 1D	10 weeks	9 weeks	N/A	N = 61 mice
Figure 1E	10 weeks	9 weeks	N/A	N = 32 mice
Figure 1I,J	14 weeks (d28)	9 weeks (d28)	N/A	N = 3 / group
	23 weeks (d90)	9 weeks (d90)	N/A	(N = 2; STZ-d90)
Figure 1L	23 weeks	10 weeks	N/A	N = 6 / group
Figure 2C,D,F	11-14 weeks (d7-d28)	9 weeks	10 weeks	N = 3 / group
Figure 3B	10 weeks	7 weeks	8 weeks	N = 6 / group
Figure 3D	15 weeks	9 weeks	11 weeks	N = 6 / group
Figure 4B	12-14 weeks (d14-d28)	9 weeks	10 weeks	N = 3 (control-d14) N = 4 (STZ-d14) N = 5 (control-d28) N = 4 (STZ-d28)
Figure 4E,F	13-21 weeks	6-14 weeks	6-15 weeks (control) 7-15 weeks (STZ)	N = 6 (control) N = 4 (STZ)
Figure 4I	14 weeks	9 weeks	10 weeks	N = 4 (control) N = 5 (STZ)
Figure 5C	15 weeks	9 weeks	11 weeks	N = 7 / group
Figure 6B	10-14 weeks (d3-d28)	9 weeks	10 weeks	N = 3 / group except control-d7 (n = 2)
Figure 6D	11-14 weeks (d7-d28)	9 weeks	10 weeks	N = 3 / group
Figure 7C,D,E, Figure 7G	12 weeks	9 weeks	10 weeks	N = 3 / group N = 7-8 / group
Figure 7I	12 weeks	9 weeks	10 weeks	N = 3 / group
Figure 8A,B	9 weeks (uninjured) 12 weeks (d14)	N/A N/A	N/A 10 weeks (d14)	N = 3 (uninjured) N = 3 (d14)
Figure 8E	6 weeks	N/A	N/A	N = 4
Figure 8G,H,I	10 weeks	N/A	8 weeks	N = 3 / group
Figure 9C,F	12 weeks	N/A	10 weeks	N = 4 / group

i.p., intraperitoneal; STZ, streptozotocin.